var title_f9_53_10064="Endosc gastric adenoma";
var content_f9_53_10064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric adenoma (noninvasive intraepithelial neoplasia)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large gastric adenoma on the lesser curve of the distal corpus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jin-Seok Jang, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10064=[""].join("\n");
var outline_f9_53_10064=null;
var title_f9_53_10065="Ancestim: International drug information";
var content_f9_53_10065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ancestim: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5027626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Stemgen (AU, CA, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F5076238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Stem Cell Factor, Human",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F5027627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For use in combination with filgrastim in patients requiring peripheral blood progenitor cell (PBPC) transplantation who are at risk of poor PBPC mobilization.",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F5027629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Ancestim should be given with filgrastim, as separate injection and at separate sites, 24 hours before to 24 hours after chemotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cytokine only mobilization: 20 mcg/kg/day until completion of apheresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Post chemotherapy mobilization: 20 mcg/kg/day, starting 24 hours after chemotherapy until completion of apheresis",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5027630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [preservative free]: 1500 mcg/mL (1.2 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10393 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10065=[""].join("\n");
var outline_f9_53_10065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027626\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5076238\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027627\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027629\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821211\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5027630\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10393\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10393|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10066="Blood in the urine (hematuria) in adults";
var content_f9_53_10066=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/53/10066/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10066/contributors\" id=\"au3613\">",
"       Adam S Feldman, MD, MPH",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/53/10066/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10066/contributors\" id=\"se49\">",
"       Richard J Glassock, MD, MACP",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/53/10066/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10066/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?9/53/10066?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      BLOOD IN THE URINE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Hematuria is the medical term for red blood cells in the urine. Red blood cells in the urine can come from the kidney (where urine is made) or anywhere in the urinary tract (",
"     <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"      figure 1",
"     </a>",
"     ). The urinary tract includes the ureters (the tubes that carry the urine from the kidneys to the bladder), the bladder (where urine is stored), and the urethra (the tube through which urine exits the body).",
"    </p>",
"    <p>",
"     Although seeing blood in the urine can be frightening, most of the time hematuria is not life threatening. However, it is important to investigate the cause of hematuria because rarely, it is caused by a serious condition.",
"    </p>",
"    <p>",
"     This article will review the potential causes, evaluation, and treatment of blood in the urine in adults. Blood in the urine in children is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/9/1169?source=see_link\">",
"      \"Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)\"",
"     </a>",
"     .) More detailed information is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"      \"Etiology and evaluation of hematuria in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF HEMATURIA",
"     </span>",
"    </p>",
"    <p>",
"     There are two main types of hematuria: gross and microscopic.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Gross hematuria &mdash; Gross hematuria means that you can see blood with the naked eye because the urine is pink, red, purplish-red, brownish-red, or tea-colored. If you see blood in your urine, you should call your healthcare provider.",
"      </li>",
"      <li>",
"       Microscopic hematuria &mdash; Microscopic hematuria means that the urine is normal in color, but there are an increased number of red blood cells seen with a microscope. It is usually discovered when a urine sample is tested with a dipstick. The results of a dipstick test are not always accurate and should be confirmed with a microscopic examination.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4883899\">",
"     <span class=\"h1\">",
"      CAUSES OF BLOOD IN THE URINE",
"     </span>",
"    </p>",
"    <p>",
"     A number of conditions can cause hematuria.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Bladder infection (also called acute cystitis), which typically causes burning or pain with urination, (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"        \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Kidney infection (also called pyelonephritis) (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?27/25/28048?source=see_link\">",
"        \"Patient information: Kidney infection (pyelonephritis) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Kidney stones, which usually present with one-sided back or flank pain that can be severe (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"        \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Certain kidney diseases",
"      </li>",
"      <li>",
"       Vigorous exercise or injury (for example, after falling off a bike and bruising a kidney)",
"      </li>",
"      <li>",
"       Enlargement of the prostate (called benign prostatic hyperplasia), which is a common problem in older men",
"      </li>",
"      <li>",
"       Cancer of the bladder, prostate, or kidney, more often in patients over age 50 (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"        \"Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Sometimes, the urine appears to have blood in it because there are other red substances (pigments) in the urine. This can happen if you eat an excessive amount of beets (called beeturia), food dyes, or certain medications (such as",
"     <span class=\"nowrap\">",
"      phenazopyridine/Pyridium&reg;).",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TESTS",
"     </span>",
"    </p>",
"    <p>",
"     There are a number of tests available to determine the cause of hematuria. Most people do not need every single test.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Urine tests &mdash; Urine tests can provide clues about the cause of hematuria. This may include a urine cytology, which uses a microscope to analyze cells from the lining of the bladder and kidney (found in the urine).",
"      </li>",
"      <li>",
"       Blood tests &mdash; Blood tests may be used to look for evidence of kidney or other diseases that can cause hematuria.",
"      </li>",
"      <li>",
"       CT scan &mdash; Computed tomography, or CT scan, is a radiologic test that examines the structure of the kidneys, ureters, and bladder. Kidney stones or abnormalities of the kidneys, ureters, and bladder can usually be seen with a CT scan. A dye is usually injected into a vein during the test, which highlights any possible abnormalities.",
"      </li>",
"      <li>",
"       Kidney ultrasound &mdash; An ultrasound of the kidney is an alternative to CT scan, and is preferred for people who are allergic to the dye used in CT. Ultrasound uses sound waves to create a picture of the kidney's structure.",
"      </li>",
"      <li>",
"       Cystoscopy &mdash; Cystoscopy is a procedure that is most often done in an office setting, but sometimes is done as a day surgery procedure. A small tube with a camera is inserted into the bladder through the urethra (",
"       <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"        figure 1",
"       </a>",
"       ). A numbing gel is applied before the tube is inserted to decrease discomfort. The vast majority of patients tolerate this procedure very well.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     During cystoscopy, the physician examines the lining of the bladder to determine if there are any abnormalities. If abnormal tissue is seen, a biopsy can be taken. The biopsy is examined with a microscope to determine if abnormal or cancerous cells are present.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Kidney biopsy &mdash; During a kidney (renal) biopsy, a clinician removes a small piece of tissue from the kidney; the tissue is later examined with a microscope for signs of kidney disease. A full description of renal biopsy is available separately. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=see_link\">",
"        \"Patient information: Renal (kidney) biopsy (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      TREATMENT OF BLOOD IN THE URINE",
"     </span>",
"    </p>",
"    <p>",
"     There is no specific treatment for hematuria. Rather, treatment is aimed at the underlying cause, if a cause can be determined. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"      \"Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"      \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"      \"Patient information: Glomerular disease overview (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Follow up testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;If no underlying cause for hematuria is found during the initial evaluation, follow up urine testing and blood pressure monitoring may be recommended every three to six months.",
"    </p>",
"    <p>",
"     This is especially true if you are at increased risk for bladder cancer. A number of factors can increase your risk of bladder cancer, including being older than 50 years, smoking cigarettes and other tobacco products, and exposure to certain industrial chemicals. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      \"Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H71\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13063118\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39250?source=see_link\">",
"      Patient information: Bladder cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/13/11474?source=see_link\">",
"      Patient information: Kidney cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=see_link\">",
"      Patient information: Rhabdomyolysis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/62/994?source=see_link\">",
"      Patient information: Disseminated intravascular coagulation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/31/37363?source=see_link\">",
"      Patient information: Glomerular disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13063162\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/9/1169?source=see_link\">",
"      Patient information: Blood in the urine (hematuria) in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/18/32036?source=see_link\">",
"      Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/25/28048?source=see_link\">",
"      Patient information: Kidney infection (pyelonephritis) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/12/31939?source=see_link\">",
"      Patient information: Bladder cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=see_link\">",
"      Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15479?source=see_link\">",
"      Acute uncomplicated cystitis, pyelonephritis, and asymptomatic bacteriuria in men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27973?source=see_link\">",
"      Exercise-induced hematuria",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/2/17445?source=see_link\">",
"      Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21690?source=see_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35881?source=see_link\">",
"      Loin pain-hematuria syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12088?source=see_link\">",
"      Thin basement membrane nephropathy (benign familial hematuria)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/10999?source=see_link\">",
"      Acute complicated cystitis and pyelonephritis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?9/53/10066/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?9/53/10066?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10066/abstract/1\">",
"      Khadra MH, Pickard RS, Charlton M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10066/abstract/2\">",
"      Murakami S, Igarashi T, Hara S, Shimazaki J. Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. J Urol 1990; 144:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10066/abstract/3\">",
"      Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology 2001; 57:599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f9_53_10066=[""].join("\n");
var outline_f9_53_10066=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           BLOOD IN THE URINE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF HEMATURIA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4883899\">",
"           CAUSES OF BLOOD IN THE URINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           TREATMENT OF BLOOD IN THE URINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\" title=\"figure 1\">",
"           Urinary tract anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10067="Norepinephrine (noradrenaline): Patient drug information";
var content_f9_53_10067=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Norepinephrine (noradrenaline): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=see_link\">",
"     see \"Norepinephrine (noradrenaline): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"     see \"Norepinephrine (noradrenaline): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levophed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levophed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may rarely cause very bad skin irritation. You will be closely watched by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691934",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to norepinephrine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12090 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10067=[""].join("\n");
var outline_f9_53_10067=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202403\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202404\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025719\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025721\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025720\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025725\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025726\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025723\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025730\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/28/16838?source=related_link\">",
"      Norepinephrine (noradrenaline): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=related_link\">",
"      Norepinephrine (noradrenaline): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10068="Patient information: Heart attack (The Basics)";
var content_f9_53_10068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15786\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8356\">",
"         Coronary heart disease",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/16/3331\">",
"          Heart attack",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"           Heart attack symptoms",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/7/38004\">",
"            Coronary artery bypass graft surgery",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/24/39298\">",
"         Patient information: Angioplasty and stenting for the heart (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/53/35667\">",
"         Patient information: Cardiac catheterization (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/54/7012\">",
"         Patient information: Coronary heart disease in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/58/34722\">",
"         Patient information: High blood pressure in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/48/11011\">",
"         Patient information: High cholesterol (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/27/21940\">",
"         Patient information: Medicines after a heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/30/32226\">",
"         Patient information: Nuclear heart testing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/14/30946\">",
"         Patient information: Treatment choices for angina (chest pain) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/2/32803\">",
"         Patient information: What can go wrong after a heart attack? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/62/31717\">",
"         Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/52/12100\">",
"         Patient information: Heart attack recovery (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/38/18020\">",
"         Patient information: Heart stents and angioplasty (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Heart attack (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/heart-attack-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13395727\">",
"      <span class=\"h1\">",
"       What is a heart attack?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A heart attack, also called myocardial infarction, or MI, is what happens when one of the arteries that supply blood to the heart gets blocked. When this happens, the part of the heart that normally gets blood from that artery is damaged. The arteries that supply blood to the heart are called the &ldquo;coronary arteries.&rdquo;",
"     </p>",
"     <p>",
"      Heart attacks are usually the result of a condition called &ldquo;coronary heart disease&rdquo; or &ldquo;coronary artery disease.&rdquo; In this disease, fatty deposits called plaques form on the walls of the coronary arteries (",
"      <a class=\"graphic graphic_figure graphicRef61785 \" href=\"UTD.htm?8/10/8356\">",
"       figure 1",
"      </a>",
"      ). These plaques sometimes break open and cause blood clots to form. Then the blood clot can block off the artery and keep blood from reaching parts of the heart muscle. That is what causes most heart attacks (",
"      <a class=\"graphic graphic_figure graphicRef60394 \" href=\"UTD.htm?3/16/3331\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395734\">",
"      <span class=\"h1\">",
"       What are the symptoms of a heart attack?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Patients often notice (",
"      <a class=\"graphic graphic_figure graphicRef52579 \" href=\"UTD.htm?1/15/1268\">",
"       figure 3",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain, pressure, or discomfort in the chest",
"       </li>",
"       <li>",
"        Pain, tingling, or discomfort in other parts of the upper body, including the arms, back, neck, jaw, or stomach",
"       </li>",
"       <li>",
"        Shortness of breath",
"       </li>",
"       <li>",
"        Nausea, vomiting, burping, or heartburn",
"       </li>",
"       <li>",
"        Sweating or cold, clammy skin",
"       </li>",
"       <li>",
"        A racing or uneven heartbeat",
"       </li>",
"       <li>",
"        Feeling dizzy or lightheaded",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you think you might be having a heart attack,",
"      <strong>",
"       call 9-1-1 right away",
"      </strong>",
"      . Do not try to get to the hospital on your own.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395741\">",
"      <span class=\"h1\">",
"       Is there a test for heart attacks?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor thinks you are having a heart attack, he or she might order 1 or more of these tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         An electrocardiogram (ECG or EKG)",
"        </strong>",
"        &mdash; This test measures the electrical activity in your heart.",
"       </li>",
"       <li>",
"        <strong>",
"         Blood tests",
"        </strong>",
"        &mdash; During a heart attack, the heart releases certain chemicals. If these chemicals are in your blood, it might mean you are having a heart attack.",
"       </li>",
"       <li>",
"        <strong>",
"         Cardiac catheterization",
"        </strong>",
"        &mdash; Cardiac (heart) catheterization is also known as cardiac &ldquo;cath&rdquo; or coronary angiography. During this test, the doctor inserts a thin plastic tube into a large artery in your leg and threads it up to your heart. Then the doctor injects a dye into the tube that shows up on an x-ray. This dye can show whether any of the arteries in your heart is clogged.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395748\">",
"      <span class=\"h1\">",
"       How is a heart attack treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you go to the hospital while you are having a heart attack, the doctors and nurses will do a few things:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        They will give you oxygen through a mask or a tube in your nose. This can help reduce the damage caused by heart attack.",
"       </li>",
"       <li>",
"        They will give you pain medicines to ease the chest pain and discomfort of a heart attack. They might also give you something to help you relax.",
"       </li>",
"       <li>",
"        They might give you a medicine called a beta blocker to reduce your heart&rsquo;s need for oxygen. This medicine can help reduce the damage caused by a heart attack.",
"       </li>",
"       <li>",
"        They will try to get blood flowing again through the clogged artery. Doctors can do this in 1 of 2 ways:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        They can give you medicines into a vein (through an &ldquo;IV&rdquo;) to break up clots.",
"       </li>",
"       <li>",
"        They can do a procedure called &ldquo;angioplasty,&rdquo; in combination with cardiac catheterization (described above). It involves inserting a metal mesh tube into the clogged artery to prop it open.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        If you cannot have angioplasty, your doctor might suggest open heart surgery, also called &ldquo;coronary artery bypass grafting,&rdquo; or &ldquo;bypass surgery&rdquo; (",
"        <a class=\"graphic graphic_figure graphicRef73589 \" href=\"UTD.htm?37/7/38004\">",
"         figure 4",
"        </a>",
"        ). During this surgery, doctors create a new path&mdash;a detour&mdash;for blood to get around the clogged portion of the artery. They do this using a combination of your own arteries and veins.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For an uncomplicated heart attack, you will likely stay in the hospital between 3 and 5 days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395755\">",
"      <span class=\"h1\">",
"       What happens after a heart attack?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After you've had a heart attack, you will probably need to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Take more medicines than before.",
"        </strong>",
"        It is very important that you take all your medicines every day, as directed. The medicines given to people who have had a heart attack can help prevent other heart attacks, and they reduce the chances of having a stroke or dying. If you can&rsquo;t afford your medicines, or if the medicines give you side effects, mention it to your doctor. There are often ways to solve these problems.",
"       </li>",
"       <li>",
"        <strong>",
"         Improve the way you eat.",
"        </strong>",
"        Try to avoid fatty and fried foods, and don&rsquo;t eat too much red meat. Instead, eat lots of fruits and vegetables, and have some low-fat dairy products.",
"       </li>",
"       <li>",
"        <strong>",
"         Lose weight, if you are overweight.",
"        </strong>",
"        Losing extra weight reduces the chance of another heart attack and can make you feel better.",
"       </li>",
"       <li>",
"        <strong>",
"         Become more active.",
"        </strong>",
"        Walking, gardening, or any activity that gets you to move more can help reduce the risk.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395762\">",
"      <span class=\"h1\">",
"       What is cardiac rehab?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Cardiac rehab&rdquo; is a type of care in which doctors, nurses, and other health professionals work with you as you learn to do the things that can protect your heart. For instance, cardiac rehab teaches you the best and safest way to become more active after you have had a heart attack. It can also teach you step-by-step how to improve your diet. Plus, cardiac rehab often offers counseling that can help you cope with your condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395769\">",
"      <span class=\"h1\">",
"       When can I have sex again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Check with your doctor about when it is safe to start having sex again after a heart attack. Having sex during the first 2 weeks could lead to more heart trouble. Some experts suggest you wait at least 6 weeks. But most people can have a full sex life after having a heart attack.",
"     </p>",
"     <p>",
"      If you are less interested in sex after a heart attack, or less able to have it, that may be because some of the medicines people take after a heart attack can interfere with sex. Still, if you have problems with sex after a heart attack, tell your doctor about it. There are often ways to deal with these problems. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13395881\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=see_link\">",
"       Patient information: Medicines after a heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=see_link\">",
"       Patient information: High blood pressure in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"       Patient information: High cholesterol (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=see_link\">",
"       Patient information: Nuclear heart testing (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=see_link\">",
"       Patient information: What can go wrong after a heart attack? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=see_link\">",
"       Patient information: Cardiac catheterization (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=see_link\">",
"       Patient information: Coronary heart disease in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/24/39298?source=see_link\">",
"       Patient information: Angioplasty and stenting for the heart (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/14/30946?source=see_link\">",
"       Patient information: Treatment choices for angina (chest pain) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=see_link\">",
"       Patient information: Heart attack recovery (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       Patient information: Heart stents and angioplasty (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"       Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/53/10068?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15786 Version 10.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10068=[""].join("\n");
var outline_f9_53_10068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395727\">",
"      What is a heart attack?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395734\">",
"      What are the symptoms of a heart attack?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395741\">",
"      Is there a test for heart attacks?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395748\">",
"      How is a heart attack treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395755\">",
"      What happens after a heart attack?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395762\">",
"      What is cardiac rehab?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395769\">",
"      When can I have sex again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13395881\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15786\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/10/8356\">",
"      Coronary heart disease",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/16/3331\">",
"       Heart attack",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/15/1268\">",
"        Heart attack symptoms",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/7/38004\">",
"         Coronary artery bypass graft surgery",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/24/39298?source=related_link\">",
"      Patient information: Angioplasty and stenting for the heart (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/53/35667?source=related_link\">",
"      Patient information: Cardiac catheterization (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=related_link\">",
"      Patient information: Coronary heart disease in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/52/12100?source=related_link\">",
"      Patient information: Heart attack recovery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/58/34722?source=related_link\">",
"      Patient information: High blood pressure in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/27/21940?source=related_link\">",
"      Patient information: Medicines after a heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=related_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/14/30946?source=related_link\">",
"      Patient information: Treatment choices for angina (chest pain) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/2/32803?source=related_link\">",
"      Patient information: What can go wrong after a heart attack? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10069="Renal effects of ACE inhibitors in heart failure";
var content_f9_53_10069=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal effects of ACE inhibitors in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10069/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10069/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10069/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10069/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10069/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10069/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10069/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/53/10069/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors are widely used in the treatment of heart failure (HF). These agents decrease the formation of angiotensin II, thereby decreasing both arteriolar and venous resistance. This \"unloading\" effect on the left ventricle results in an elevation in cardiac output, symptomatic improvement, and a 25 percent decrease in cardiovascular mortality at 1 to 3 years, due primarily to a slower rate of progressive cardiac dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In addition, the administration of an ACE inhibitor after an acute myocardial infarction can preserve cardiac function (as evidenced by an increased ejection fraction and decreased ventricular size) and improve long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ACE inhibitor given with a loop diuretic may have the additional advantage of raising the plasma sodium concentration in patients with HF and hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/6\">",
"     6",
"    </a>",
"    ]. This synergism may reflect the interaction of two factors that results in an increase in free water excretion: (1) increased water delivery to the collecting tubules by the loop diuretic (due to the decline in loop reabsorption); and (2) diminished water reabsorption in the collecting tubules due both to reduced secretion of antidiuretic hormone (ADH) (via the rise in cardiac output) and perhaps to ADH resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to a possible elevation in free water excretion, ACE inhibitors have other renal actions in HF, including changes in the glomerular filtration rate, reduced potassium excretion that can lead to hyperkalemia, and a variable alteration in the natriuretic response to diuretics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECT ON GLOMERULAR FILTRATION RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the improvement in cardiac output and in renal blood flow, it might be assumed that ACE inhibitors would also increase the glomerular filtration rate (GFR). However, this expected response occurs in only 10 to 25 percent of patients, while an increase in the plasma creatinine concentration is a more common finding [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. As an example, the CONSENSUS trial of patients with severe HF noted a mean elevation in the plasma creatinine concentration of 0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10 to 20",
"    <span class=\"nowrap\">",
"     &micro;mol/L);",
"    </span>",
"    furthermore, 11 percent of patients had more than a 100 percent rise in the plasma creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/8\">",
"     8",
"    </a>",
"    ]. This usually modest decline in GFR occurs within the first week; renal function then tends to be stable unless a complicating factor, such as worsening of cardiac function is superimposed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reduction in GFR in HF is most likely to occur in those settings in which maintenance of the GFR is dependent upon high ambient angiotensin II levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients on high-dose diuretic therapy in whom there is relative hypovolemia due to an excessive diuretic response.",
"     </li>",
"     <li>",
"      Patients with relative hypotension (mean arterial pressure below 75 mmHg) after therapy, which is usually reflective of a low cardiac output.",
"     </li>",
"     <li>",
"      Patients with a pretreatment plasma sodium concentration below 137",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      since this is a marker for marked neurohumoral activation.",
"     </li>",
"     <li>",
"      Patients with significant renovascular disease, a common finding among the elderly with HF [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In theory, the plasma renin activity should also identify patients at risk. However, measurement of the plasma renin activity is not a useful clinical test because circulating renin may not reflect the activity of",
"    <strong>",
"     tissue",
"    </strong>",
"    renin-angiotensin systems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, patients with stable HF may have a normal plasma renin activity despite having a persistent reduction in cardiac output that is as low as in unstable patients with hyperreninemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/11\">",
"     11",
"    </a>",
"    ]. Studies in animals with heart failure have shown that the intrarenal renin-angiotensin system may still be activated in this setting, an appropriate response to the fall in renal perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, an ACE inhibitor may lower the GFR by decreasing intrarenal angiotensin II.",
"   </p>",
"   <p>",
"    The ACE inhibitor-induced fall in GFR in HF is due at least in part to a preferential reduction in efferent arteriolar resistance in the glomerulus, which leads to a reduction in intraglomerular pressure, which is the primary driving force for glomerular filtration The baseline level of glomerular filtration can often be restored by lowering the diuretic dose, thereby decreasing the angiotensin II-dependence of glomerular filtration. In addition, use of nonsteroidal antiinflammatory drugs should be avoided, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link&amp;anchor=H6654443#H6654443\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Effect on GFR'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=see_link&amp;anchor=H7#H7\">",
"     \"Nonselective NSAIDs: Adverse cardiovascular effects\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been suggested that a decline in GFR may be less likely to occur with a short-acting ACE inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/13\">",
"     13",
"    </a>",
"    ]. This observation was based upon a study in which relatively high doses were used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/13\">",
"     13",
"    </a>",
"    ]. Initiating therapy with a low dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    (as with 2.5 mg of enalapril) is probably as safe as captopril in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/1,6,14\">",
"     1,6,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in experimental animals suggest that there may be differences in the degree to which individual ACE inhibitors inhibit tissue converting enzyme in the presence of HF. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    may be a more potent inhibitor of renin ACE than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ; rather than leading to a reduction in GFR, this change may lead to a moderate increase in sodium excretion, a possible reflection of diminished proximal sodium reabsorption due to removal of the normal stimulatory effect of angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/15\">",
"     15",
"    </a>",
"    ]. The relevance of these findings to humans remains to be proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decline in GFR induced by an ACE inhibitor in HF can be minimized or prevented by the combination of low initial doses plus a transient decrease in diuretic dosage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/7\">",
"     7",
"    </a>",
"    ]. The plasma creatinine and potassium concentrations should be measured within the first week, since a deleterious change in renal hemodynamics or potassium excretion should occur in this time period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/8\">",
"     8",
"    </a>",
"    ]. Even with optimal management, however, some patients are so angiotensin II-dependent that switching to the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    (which does not preferentially diminish efferent arteriolar resistance) may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HYPERKALEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with underlying renal insufficiency are also at higher risk for the development of hyperkalemia following the administration of an ACE inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. Advanced heart failure is associated with decreased sodium and water delivery to the potassium secretory site in the collecting tubules. Maintenance of adequate potassium secretion in these patients is dependent upon increased secretion of aldosterone, a response that may be partially impaired if there is diminished production of angiotensin II (since angiotensin II is the primary mediator of the hypoperfusion-induced increase in aldosterone release).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NATRIURETIC RESPONSE TO DIURETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors appear to have a variable effect on the natriuretic response to diuretics that reflects the interplay between multiple factors and the timing of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/18\">",
"     18",
"    </a>",
"    ]. When acutely given in very low doses (eg, 1 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    ), the response to a loop diuretic is enhanced. This may be mediated by a decline in proximal sodium reabsorption induced by the reduction in intrarenal angiotensin II. The GFR is stable in this setting, presumably because sufficient angiotensin II is available to sustain efferent arteriolar tone. At higher doses, however, both a fall in systemic blood pressure and, as described above, a decrease in GFR can occur. These hemodynamic changes tend to promote sodium conservation and may attenuate the diuretic response by as much as 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical relevance of these observations is uncertain, since they were obtained after the administration of a single dose of an ACE inhibitor. One study that evaluated patients chronically treated with 12.5 mg three times daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    found that ACE inhibition moderately increased the diuretic response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    by about 20 percent, despite reductions in blood pressure and glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10069/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, reversal of angiotensin II-induced proximal reabsorption may be of primary importance in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27655912\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About 10 to 25 percent of patients with heart failure (HF) have improvement in renal function after initiation of angiotensin converting enzyme (ACE) inhibitors, presumably due sequentially to an improvement in cardiac output and increase in renal blood flow. However, a worsening of glomerular filtration rate (GFR) is more common. Worsening of GFR is due at least in part to reduction of efferent arteriolar resistance superimposed on relatively low renal perfusion. A reduction in GFR in HF is most likely to occur in the following settings (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Effect on glomerular filtration rate'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients on diuretic therapy in whom there is relative hypovolemia",
"     </li>",
"     <li>",
"      Patients with relative hypotension (mean arterial pressure below 75 mmHg) after therapy",
"     </li>",
"     <li>",
"      Patients with a pretreatment plasma sodium concentration below 137",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Patients with significant renovascular disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This usually modest decline in GFR occurs within the first week; renal function then tends to be stable unless a complicating factor, such as worsening of cardiac function, is superimposed. Thus, the plasma creatinine and potassium concentrations should be measured within the first week, since a deleterious change in renal hemodynamics or potassium excretion should occur in this time period. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with underlying renal insufficiency are also at higher risk for the development of hyperkalemia following the administration of an ACE inhibitor. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hyperkalemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/1\">",
"      Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/2\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/3\">",
"      Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA 1988; 259:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/4\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/5\">",
"      Pfeffer MA, Braunwald E, Moy&eacute; LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/6\">",
"      Oster JR, Materson BJ. Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 1992; 152:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/7\">",
"      Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/8\">",
"      Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992; 70:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/9\">",
"      Packer M, Lee WH, Kessler PD, et al. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol 1987; 10:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/10\">",
"      MacDowall P, Kalra PA, O'Donoghue DJ, et al. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet 1998; 352:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/11\">",
"      Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/12\">",
"      Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992; 90:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/13\">",
"      Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/14\">",
"      Giles TD, Katz R, Sullivan JM, et al. Short- and long-acting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol 1989; 13:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/15\">",
"      Hirsch AT, Talsness CE, Smith AD, et al. Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. Circulation 1992; 86:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/16\">",
"      Packer M, Lee WH, Medina N, Yushak M. Influence of renal function on the hemodynamic and clinical responses to long-term captopril therapy in severe chronic heart failure. Ann Intern Med 1986; 104:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/17\">",
"      Textor SC, Bravo EL, Fouad FM, Tarazi RC. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 1982; 73:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/18\">",
"      Motwani JG, Fenwick MK, Morton JJ, Struthers AD. Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation 1992; 86:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/19\">",
"      McLay JS, McMurray JJ, Bridges AB, et al. Acute effects of captopril on the renal actions of furosemide in patients with chronic heart failure. Am Heart J 1993; 126:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10069/abstract/20\">",
"      Good JM, Brady AJ, Noormohamed FH, et al. Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation 1994; 90:220.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2365 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10069=[""].join("\n");
var outline_f9_53_10069=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27655912\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECT ON GLOMERULAR FILTRATION RATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HYPERKALEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NATRIURETIC RESPONSE TO DIURETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27655912\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13175?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Recommendations for use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24648?source=related_link\">",
"      Nonselective NSAIDs: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10070="Management of multiple magnet ingestion";
var content_f9_53_10070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86069&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 650px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of multiple magnet ingestion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 630px; height: 741px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If magnet might be, or is known to be, a high-powered type (neodymium, or \"rare earth\" type).",
"     <br>",
"      &Delta;&nbsp;Radiographs do not reliably distinguish between single and multiple magnets, since it is possible for magnets to stick together or overlap on a radiograph, and be misdiagnosed as a single magnet.&nbsp;",
"      <br>",
"       &loz; The following \"magnet precautions\" should be used for any child&nbsp;who has ingested one or more magnets: Remove any magnetic objects nearby, avoid clothes with metallic buttons and belts with buckles, and ensure that no other metal objects or magnets are in the child's environment that could be accidentally ingested. Maintain these precautions until the magnet has passed out of the gastrointestinal tract.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified&nbsp;with permission from: Hussain SZ, Bousvaros A, Gilger M, et al. Management of ingested magnets in children. J Pediatr Gastroenterol Nutr 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10070=[""].join("\n");
var outline_f9_53_10070=null;
var title_f9_53_10071="Hepatosplenic candidiasis (chronic disseminated candidiasis)";
var content_f9_53_10071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatosplenic candidiasis (chronic disseminated candidiasis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10071/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10071/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10071/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10071/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10071/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/53/10071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatosplenic candidiasis (also called chronic disseminated candidiasis) is seen almost entirely in patients with hematologic malignancies who have just recovered from an episode of neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Very few cases, some of which were not well documented, have been reported in patients who did not have leukemia or neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical issues related to hepatosplenic candidiasis will be reviewed here. An overview of Candida infections as well as the clinical manifestations, diagnosis, and treatment of candidemia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of hepatosplenic candidiasis is not well understood, but this entity is thought to result from invasion of Candida species from the gastrointestinal tract into the bloodstream as a result of prolonged neutropenia and a breach in mucosal integrity. The portal system may receive the largest inoculum and hence disease is prominent in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatosplenic candidiasis occurs almost exclusively in patients with acute leukemia, but has been reported rarely in patients with lymphoma, aplastic anemia, and sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which hepatosplenic candidiasis occurs in adults with acute leukemia was evaluated in 562 patients seen between 1980 and 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/5\">",
"     5",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty-eight patients (7 percent) developed hepatosplenic candidiasis.",
"     </li>",
"     <li>",
"      The incidence was significantly higher with acute lymphoblastic leukemia than acute myeloid leukemia (11 versus 5 percent).",
"     </li>",
"     <li>",
"      The incidence increased fivefold during the study period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, hepatosplenic candidiasis is now seen less frequently because of the widespread use of antifungal agents for prophylaxis or early initiation of empiric antifungal therapy for neutropenic fevers in high-risk leukemic and stem cell transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. The potential magnitude of this effect was illustrated in an autopsy study performed between 1990 and 1994 in 329 hematopoietic stem cell transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    prophylaxis had, when compared to those who were not treated with fluconazole, significantly lower rates of Candida infections (8 versus 27 percent) and hepatic candidiasis (3 versus 16 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for hepatosplenic candidiasis include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute leukemia",
"     </li>",
"     <li>",
"      Prolonged neutropenia (most commonly resulting from cytotoxic chemotherapy)",
"     </li>",
"     <li>",
"      Intravascular catheters",
"     </li>",
"     <li>",
"      Disruption of mucosal barriers",
"     </li>",
"     <li>",
"      Administration of broad-spectrum antibiotics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who do not receive antifungal prophylaxis (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ) are also likely to be at increased risk of hepatosplenic candidiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all cases of hepatosplenic candidiasis in which an organism has been identified have been due to C. albicans; however, other species, including C. tropicalis, C. parapsilosis, C. glabrata, and C. krusei, have occasionally been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/1,3,5,7,8\">",
"     1,3,5,7,8",
"    </a>",
"    ]. It seems likely that non-albicans Candida species will increase as a cause of hepatosplenic candidiasis because of the increase in non-albicans species as a cause of candidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\", section on 'Susceptibility patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic presentation of hepatosplenic candidiasis consists of persistent fever that is frequently high and spiking in a patient who was previously neutropenic and whose neutrophil count has returned to normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Patients can be febrile for weeks if the diagnosis is not made in a timely manner, and in one series, patients remained febrile for months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H9533717#H9533717\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Fungal pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fever is often accompanied by right upper quadrant discomfort or pain, nausea, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anorexia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/7,11\">",
"     7,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing typically reveals an elevated serum alkaline phosphatase concentration, which may remain elevated for months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/2\">",
"     2",
"    </a>",
"    ]. In one study, 24 of 28 patients (86 percent) had a three- to fivefold elevation of alkaline phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/11\">",
"     11",
"    </a>",
"    ]. Less common laboratory abnormalities include mildly elevated aspartate aminotransferase, alanine aminotransferase, and bilirubin, as well as leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients have a documented prior episode of candidemia (32 percent in a series of 28 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/11\">",
"     11",
"    </a>",
"    ]. In others, it is assumed that the patient was candidemic during the period of neutropenia, or that invasion occurred through the portal vasculature, without corresponding positive venous blood cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=see_link\">",
"     \"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) scanning, ultrasonography, or magnetic resonance imaging (MRI) during neutrophil recovery reveals characteristic multiple lucencies, which represent microabscesses, in the liver, spleen, and sometimes the kidneys (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64691 \" href=\"UTD.htm?27/56/28545\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/1,10\">",
"     1,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT is the imaging modality of choice given its sensitivity of approximately 57 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ]. By comparison, ultrasonography has a sensitivity of 33 to 75 percent. If CT does not reveal the typical lesions in a patient in whom hepatosplenic candidiasis is suspected, an MRI should be performed, since it has the highest sensitivity among the imaging modalities (&gt;95 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, initial imaging with CT is preferred since it is less expensive and simpler to perform.",
"   </p>",
"   <p>",
"    The importance of neutrophils in the lesions of hepatosplenic candidiasis has been demonstrated by serial CT scanning, which may show disappearance of hepatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenic lesions during neutropenia with reappearance after neutrophil recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis can be established only by biopsy, which reveals multiple granulomas and, with special stains, yeasts and hyphal forms (",
"    <a class=\"graphic graphic_picture graphicRef81112 \" href=\"UTD.htm?39/46/40674\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/1\">",
"     1",
"    </a>",
"    ]. Cultures of hepatic tissue obtained at biopsy are usually negative, particularly if antifungal therapy has been given; hence, a negative biopsy does not rule out the diagnosis.",
"   </p>",
"   <p>",
"    Although biopsy is the gold standard, it often cannot be performed because the patient is thrombocytopenic. Fortunately, for almost every patient, the clinical, laboratory, and imaging characteristics are sufficiently specific that biopsy is not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of therapy for hepatosplenic candidiasis is antifungal therapy, most commonly with a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . For clinically stable patients, oral fluconazole may be given initially. Treatment requires a long duration of antifungal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antifungal therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials evaluating the efficacy of antifungal drugs in the treatment of hepatosplenic candidiasis have not been performed.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    deoxycholate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    have been studied most extensively for the treatment of hepatosplenic candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/16\">",
"     16",
"    </a>",
"    ]. The following observations have been made based upon small open-label studies and case reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      deoxycholate has been variably successful [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/1,7,10,17\">",
"       1,7,10,17",
"      </a>",
"      ]. Lipid formulations are probably more effective than amphotericin B deoxycholate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/2,18,19\">",
"       2,18,19",
"      </a>",
"      ], but some patients do not respond [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (200 to 800 mg daily) has been effective for either step-down therapy (following a course of induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/7,10\">",
"       7,10",
"      </a>",
"      ] or primary therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/21\">",
"       21",
"      </a>",
"      ]. One report, for example, evaluated six patients with acute leukemia and hepatosplenic candidiasis who had not responded to prior therapy with amphotericin B with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/10\">",
"       10",
"      </a>",
"      ]. Fluconazole therapy was given for 2 to 14 months. In all patients, fever and other symptoms resolved in two to eight weeks, lesions improved on CT scan in four to eight weeks, and the lesions resolved in four weeks to five months in five patients and 13 months in one patient.",
"      <br/>",
"      <br/>",
"      Similar findings were noted in a series of 20 consecutive patients who were treated with fluconazole (100 to 400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for a median of 30 weeks) after either failure to respond to or tolerate amphotericin B&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/7\">",
"       7",
"      </a>",
"      ]. A response was noted in 14 of 16 evaluable patients. In 12 patients, chemotherapy was continued without a flare of the Candida infection. Aspergillus superinfection developed in three patients and contributed to the death of two patients.",
"     </li>",
"     <li>",
"      Individual case reports document the success of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       caspofungin",
"      </a>",
"      , with or without an azole, in treating hepatosplenic candidiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/20,22,23\">",
"       20,22,23",
"      </a>",
"      ]. However, failures have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antifungal regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2009 Infectious Diseases Society of America (IDSA) guidelines for the management of candidiasis, which includes the following recommendations regarding the treatment of hepatosplenic candidiasis (",
"    <a class=\"graphic graphic_table graphicRef87678 \" href=\"UTD.htm?31/31/32251\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In acutely ill patients or in those with refractory disease, a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily) is recommended. Induction therapy with lipid amphotericin B for one to two weeks should be followed by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 mg [6",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      daily).",
"     </li>",
"     <li>",
"      Echinocandins are recommended as an alternative induction regimen for one to two weeks, followed by oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 mg [6",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      daily). The recommended doses of the echinocandins are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      &mdash; 70 mg loading dose, then 50 mg intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       Anidulafungin",
"      </a>",
"      &mdash; 200 mg loading dose, then 100 mg intravenously daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      &mdash; 100 mg intravenously daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the IDSA guidelines recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.5 to 0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily) as an alternative to a lipid formulation of amphotericin B, it is the least favorable option given its toxicity. In addition, in our experience, many patients with hepatosplenic candidiasis do not respond to this formulation.",
"     </li>",
"     <li>",
"      For clinically stable patients, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      400 mg [6",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      daily may be given initially.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon clinical experience, we suggest that antifungal therapy should be continued until there is resolution or calcification of the lesions on follow-up CT scans, which are usually obtained every two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/16\">",
"     16",
"    </a>",
"    ]. Resolution of lesions occurs within six months in most, but not all, patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/7\">",
"     7",
"    </a>",
"    ]. As noted above, the hepatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenic lesions can appear and disappear as the patient's neutrophil count rises and falls, respectively; such changes do not signify the failure or success of antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapy must be continued through periods of increased risk (eg, subsequent courses of chemotherapy, hematopoietic stem cell transplantation) in order to prevent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy, in combination with antifungal therapy, has occasionally been performed when the burden of abscesses is almost entirely in the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adjuvant glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because hepatosplenic candidiasis occurs following neutrophil recovery in patients being treated for acute leukemia, it has been proposed that this entity may represent a form of immune reconstitution inflammatory syndrome (IRIS) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective, multicenter study assessed the efficacy of oral glucocorticoids in 10 children and adults who had ongoing symptomatic probable or proven chronic disseminated candidiasis despite appropriate antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10071/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients who received a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    equivalent of &ge;0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for at least three weeks had prompt resolution of fever and abdominal pain (median 4 to 5 days) and of the inflammatory response as measured by serum fibrinogen and C-reactive protein levels (range 14 to 30 days). However, the time to radiographic improvement (mean 106 days) was similar to that for historical controls. No relapses of candidiasis were observed. Further studies will need to be performed in order to determine the safety and efficacy of adjuvant glucocorticoids for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatosplenic candidiasis (also called chronic disseminated candidiasis) is seen almost entirely in patients who have hematologic malignancies and who have just recovered from an episode of neutropenia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases in which an organism has been identified have been due to C. albicans; however, other species, including C. tropicalis, C. parapsilosis, C. glabrata, and C. krusei, have occasionally been reported. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic presentation of hepatosplenic candidiasis consists of persistent fever that is frequently high and spiking in a patient who was previously neutropenic and whose neutrophil count has returned to normal. The fever is often accompanied by right upper quadrant discomfort or pain, nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anorexia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory testing typically reveals an elevated serum alkaline phosphatase concentration. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography (CT) scanning during neutrophil recovery reveals characteristic multiple lucencies in the liver, spleen, and sometimes the kidneys. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A definitive diagnosis can be established only by biopsy, which reveals multiple granulomas and, with special stains, yeasts and hyphal forms (",
"      <a class=\"graphic graphic_picture graphicRef81112 \" href=\"UTD.htm?39/46/40674\">",
"       picture 1",
"      </a>",
"      ). Cultures of hepatic tissue obtained at biopsy are usually negative, particularly if antifungal therapy has been given.",
"      <br/>",
"      <br/>",
"      Although biopsy is the gold standard, it often cannot be performed because the patient is thrombocytopenic. Fortunately, for almost every patient, the clinical, laboratory, and imaging characteristics are sufficiently specific that biopsy is not required. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In acutely ill patients or in those with refractory disease, we suggest a lipid formulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily). Alternatives include echinocandins and amphotericin B deoxycholate (0.5 to 0.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously daily), although the latter of these is clearly is more toxic than the other options (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The recommended doses of the echinocandins are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10486?source=see_link\">",
"       Caspofungin",
"      </a>",
"      &mdash; 70 mg loading dose, then 50 mg intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/51/20276?source=see_link\">",
"       Anidulafungin",
"      </a>",
"      &mdash; 200 mg loading dose, then 100 mg intravenously daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/31/44532?source=see_link\">",
"       Micafungin",
"      </a>",
"      &mdash; 100 mg intravenously daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following one to two weeks of induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or an echinocandin, we suggest transitioning to therapy with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      (400 mg [6",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      daily) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For clinically stable patients, we suggest that oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      400 mg [6",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      daily be given initially rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or an echinocandin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Antifungal therapy should be continued until there is resolution or calcification of the lesions on follow-up CT scans. Resolution of lesions occurs within six months in most, but not all, patients. The hepatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      splenic lesions can appear and disappear as the patient's neutrophil count rises and falls, respectively; such changes do not signify the failure or success of antifungal therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy must be continued through periods of increased risk (eg, subsequent courses of chemotherapy, hematopoietic stem cell transplantation) in order to prevent relapse. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/1\">",
"      Thaler M, Pastakia B, Shawker TH, et al. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann Intern Med 1988; 108:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/2\">",
"      Kontoyiannis DP, Luna MA, Samuels BI, Bodey GP. Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect Dis Clin North Am 2000; 14:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/3\">",
"      Spindel SJ, Darouiche RO, Saeed ZA. Hepatosplenic candidiasis in non-neutropenic patients: a case report and literature survey. Int J Antimicrob Agents 1996; 7:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/4\">",
"      Cole GT, Lynn KT, Seshan KR. Evaluation of a murine model of hepatic candidiasis. J Clin Microbiol 1990; 28:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/5\">",
"      Anttila VJ, Elonen E, Nordling S, et al. Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis 1997; 24:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/6\">",
"      van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/7\">",
"      Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991; 91:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/8\">",
"      Ratip S, Odaba��i Z, Karti S, et al. Clinical microbiological case: chronic disseminated candidiasis unresponsive to treatment. Clin Microbiol Infect 2002; 8:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/9\">",
"      Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/10\">",
"      Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991; 91:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/11\">",
"      Pagano L, Mele L, Fianchi L, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica 2002; 87:535.",
"     </a>",
"    </li>",
"    <li>",
"     Samuels, BI, Pagani, JJ, Libshitz, HI. Radiologic features of Candida infections. In: Candidiasis: Pathogenesis, Diagnosis and Treatment, Bodey, GP (Ed), Raven Press, New York 1993. p. 137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/13\">",
"      Anttila VJ, Lamminen AE, Bondestam S, et al. Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. Eur J Haematol 1996; 56:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/14\">",
"      Semelka RC, Kelekis NL, Sallah S, et al. Hepatosplenic fungal disease: diagnostic accuracy and spectrum of appearances on MR imaging. AJR Am J Roentgenol 1997; 169:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/15\">",
"      Pestalozzi BC, Krestin GP, Schanz U, et al. Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia. Blood 1997; 90:3858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/16\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/17\">",
"      Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995; 76:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/18\">",
"      Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/19\">",
"      Gokhale PC, Barapatre RJ, Advani SH, et al. Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report. J Cancer Res Clin Oncol 1993; 119:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/20\">",
"      Sor&agrave; F, Chiusolo P, Piccirillo N, et al. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis 2002; 35:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/21\">",
"      de Pauw BE, Raemaekers JM, Donnelly JP, et al. An open study on the safety and efficacy of fluconazole in the treatment of disseminated Candida infections in patients treated for hematological malignancy. Ann Hematol 1995; 70:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/22\">",
"      Kontny U, Walsh TJ, Rossler J, et al. Successful treatment of refractory chronic disseminated candidiasis after prolonged administration of caspofungin in a child with acute myeloid leukemia. Pediatr Blood Cancer 2007; 49:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/23\">",
"      H&uuml;bel K, Chemnitz J, Brochhagen HG, Cornely OA. Successful treatment of chronic disseminated candidiasis with caspofungin and itraconazole in a patient with progressive acute leukemia and prolonged neutropenia. Int J Hematol 2004; 79:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/24\">",
"      Vehreschild JJ, Kr&uuml;ger K, Kurzai O, et al. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses 2006; 49 Suppl 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10071/abstract/25\">",
"      Legrand F, Lecuit M, Dupont B, et al. Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clin Infect Dis 2008; 46:696.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2425 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-115.25.216.6-3DB58A19CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10071=[""].join("\n");
var outline_f9_53_10071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antifungal regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adjuvant glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2425\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2425|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/56/28545\" title=\"diagnostic image 1\">",
"      CT of hepatosplenic candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2425|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/46/40674\" title=\"picture 1\">",
"      Hepatic candidiasis histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2425|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/31/32251\" title=\"table 1\">",
"      Treatment of hepatosplenic candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36966?source=related_link\">",
"      Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10072="Women and lung cancer";
var content_f9_53_10072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Women and lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10072/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10072/contributors\">",
"     Elizabeth H Baldini, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10072/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10072/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10072/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10072/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10072/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/53/10072/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemic of lung cancer in women is reviewed here, focusing on epidemiologic issues, risk factors, outcome, and prevention. General issues related to lung cancer risk and its clinical presentation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, lung cancer is the fourth most common cancer in women, behind breast, colon and rectum, and cervical cancers, accounting for 514,000 cases and 427,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, lung cancer is now the leading cancer killer of women, having surpassed breast cancer in 1987 (",
"    <a class=\"graphic graphic_table graphicRef82580 \" href=\"UTD.htm?12/2/12331\">",
"     table 1",
"    </a>",
"    ). Almost twice as many women in the United States are expected to die from lung cancer compared with breast cancer in 2013 (72,220 versus 39,620) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age-adjusted lung cancer death rate has risen in parallel to the smoking rate among women, with the curves separated by approximately 20 years. The 20 year separation reflects the latency period between smoking and death from lung cancer. Specifically, the smoking rate for women rose in the United States from 1930 to 1960, which was followed by a rapidly increasing lung cancer death rate that began in 1960 (",
"    <a class=\"graphic graphic_figure graphicRef58335 \" href=\"UTD.htm?21/35/22077\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. The lung cancer death rate in women has reached a plateau and has now started to decline with a reported decrease of 1.1 percent per year from 2003 to 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/7\">",
"     7",
"    </a>",
"    ]. The same trend has been documented in many European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Comparison of men and women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer mortality has always been and continues to be more common in men than women. However, the magnitude of this difference continues to decline due to increases in the female lung cancer mortality rate while the mortality rate in males has decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age-adjusted lung cancer incidence continues to be higher in men than women. However, the magnitude of this difference is also decreasing, which reflects the fact that the female incidence rate is stabilizing while the male incidence rate continues to decrease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A notable exception to these trends exists among never smokers. In this population, the age-adjusted incidence rate of lung cancer is higher for women (14.4 to 20.8 per 100,000 person-years) than men (4.8 to 13.7 per 100,000 person-years) according to a pooled analysis of six prospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, in the US, approximately 19 percent of lung cancer in women arises in never smokers compared to only 9 percent for men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12394?source=see_link\">",
"     \"Lung cancer in never smokers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that smoking is the most important risk factor for the development of lung cancer in both women and men, the question arises whether there is a gender-related difference in the magnitude of the relationship between smoking and lung cancer. An additional question is whether endocrine factors affect the risk of lung cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is the main culprit for the lung cancer epidemic in women, with estimates suggesting up to 80 percent of lung cancer cases in women are related to smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Women started smoking in significant numbers during and following World War II. Although smoking rates have declined since their peak in the 1960s, the current prevalence of smoking among women in the United States is still too high at about 18 percent in 2006 (",
"    <a class=\"graphic graphic_figure graphicRef65613 \" href=\"UTD.htm?4/58/5038\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/13,15-17\">",
"     13,15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reported relative risks (RR) for the development of lung cancer in women smokers compared to women non-smokers range from 1.5 to 153 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/14,18-24\">",
"     14,18-24",
"    </a>",
"    ]. Furthermore, the magnitude of the risk increases with the duration of smoking and with the total exposure to cigarettes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/14,22-24\">",
"     14,22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is not clear whether the strength of the association between smoking and lung cancer is different for women than for men, since studies that address this issue provide conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some reports show a higher RR for the development of lung cancer among women smokers than men smokers [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other studies have demonstrated similar odds ratios (OR) for lung cancer among male and female smokers with comparable levels of exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/22,25\">",
"       22,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these conflicting data, it is difficult to discern whether the magnitude of the association between cigarette smoking and lung cancer is different for women than for men. There are a number of factors that may have accounted for the differing results. The intensity of smoking was variably assessed in these studies, which may be one explanation for the conflicting results. In addition, case-control studies are prone to potentially significant biases; they are retrospective and subject to misclassification and selection biases.",
"   </p>",
"   <p>",
"    Furthermore, case-control studies only provide information with respect to relative risks. Absolute risks, which are perhaps more meaningful from a public health standpoint, can only be assessed through prospective population-based studies. Finally, since the background incidence of lung cancer among men and women nonsmokers may differ, it is not appropriate to make conclusions about the susceptibility of women versus men smokers to the development of lung cancer based solely on a RR statistic [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lung cancer is not the only smoking-related tragedy in women. The World Health Organization showed that at least 25 percent of women smokers die from a smoking-related disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/15\">",
"     15",
"    </a>",
"    ]. In absolute numbers, approximately 300,000 women in developed countries died of smoking-related diseases in 1985. The most important smoking-related causes of death were cardiovascular disease (41 percent), lung cancer (21 percent), and chronic obstructive pulmonary disease (18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/15\">",
"     15",
"    </a>",
"    ]. Other causes include cancers of the esophagus, head and neck, and other sites, as well as other respiratory diseases. A more recent report estimated that in 2000 there were 4.83 million deaths in the world due to smoking with an even split between industrialized and non-industrialized countries. About one million of these deaths were in women, and the principal causes of death remained cardiovascular disease, lung cancer, and chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H953397484\">",
"    <span class=\"h2\">",
"     Air pollution",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a relatively high burden of lung cancer in women in China and certain other countries in Asia and Africa, which is thought to be due to burning coal and wood for cooking in unventilated stoves [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link&amp;anchor=H1560496527#H1560496527\">",
"     \"Cigarette smoking and other risk factors for lung cancer\", section on 'Smoke from cooking and heating'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to radiation is a known risk factor for subsequent development of lung cancer, as well as other cancers. Data from atomic bomb survivors document increased lung cancer incidence years following this exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/29\">",
"     29",
"    </a>",
"    ]. Similarly, several reports have shown that survivors of Hodgkin lymphoma who have received radiation therapy (RT) to the chest have a higher risk of developing a lung cancer compared to those who did not receive RT; this risk is further increased among smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings have been reported in women who have received radiation therapy for breast cancer. The incidence of lung cancer is markedly increased in women who have smoked and have received radiation therapy following mastectomy for breast cancer compared to those who never smoked and did not receive post-mastectomy RT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endocrine factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies yielded conflicting data regarding the effect of hormonal factors on the risk of lung cancer in women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/4,34-39\">",
"     4,34-39",
"    </a>",
"    ], although large randomized studies suggest that estrogen plus progestin therapy is associated with an increased risk of lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most extensive data come from three prospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Women's Health Initiative trial, 16,806 women were randomly assigned to estrogen-progestin therapy or placebo. There was a statistically nonsignificant trend toward an increased incidence of non-small cell lung cancer in women taking estrogen-progestin therapy when compared to placebo (0.14 versus 0.11 percent, hazard ratio [HR] 1.28, 95% CI 0.94-1.73), and an increased number of deaths from lung cancer (0.11 versus 0.06 percent, HR 1.71, 95% CI 1.16-2.52) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/40,41\">",
"       40,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another component of the Women's Health Initiative trial, 10,739 women who had previously undergone a hysterectomy were randomly assigned to estrogen alone or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/43\">",
"       43",
"      </a>",
"      ]. In a post-hoc analysis, there was no statistically significant increase in the incidence of lung cancer after a mean follow-up of eight years (HR for incidence 1.17, 95% CI 0.81-1.69) nor was there an increase in deaths from lung cancer (HR for death 1.07, 95% CI 0.66-1.72).",
"     </li>",
"     <li>",
"      The prospective Vitamins and Lifestyle (VITAL) Study followed a cohort of over 36,000 peri- and post-menopausal women during six years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/42\">",
"       42",
"      </a>",
"      ]. After adjusting for smoking and other confounding factors, the risk of incident lung cancer was increased for those who used an estrogen plus progestin. The risk was proportional to duration of hormone exposure (hazard ratio [HR] 1.48, 95% CI 1.03-2.12 for those with &ge;10 years exposure to an estrogen plus progestin).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endocrine factors also may have an impact on the natural history of disease if lung cancer does develop [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors other than smoking that have been established for the development of lung cancer in men have also been confirmed for women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"     \"Cigarette smoking and other risk factors for lung cancer\"",
"    </a>",
"    .) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A family history of lung cancer, which is both a risk factor on its own and has a significant interaction with smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/23,45\">",
"       23,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A history of prior lung disease, which is a known risk factor in men and has been shown to be a risk factor in two case-control studies limited to women [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/46,47\">",
"       46,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An unresolved issue for both men and women is the relation between diet and vitamins and the development of lung cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/48-52\">",
"       48-52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a consistent difference in the distribution of histologic types of lung cancer between men and women. The most common histologic types continue to be adenocarcinoma in women and squamous cell carcinoma in men [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. Rates of all lung cancer types in women and adenocarcinoma in men continue to rise [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Part of the explanation for differing distributions of lung cancer histology between women and men could be related to differences in smoking patterns. However, this explanation cannot fully account for the observed differences. For example, men smokers have a similar odds ratio for the development of squamous cell and small cell carcinomas, whereas women smokers appear to have a much higher odds ratio for the development of small cell compared with squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/24,59,60\">",
"     24,59,60",
"    </a>",
"    ]. It has been suggested, although not definitively demonstrated, that estrogen may influence histologic and molecular features of lung cancer and may explain some of the observed inter-gender differences in these characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although early series suggested that the outcome of lung cancer treatment was worse in women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/62-64\">",
"     62-64",
"    </a>",
"    ], contemporary studies indicate that the prognosis in women is better than in men, at least for patients with adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis from the Surveillance, Epidemiology and End Results (SEER) and Medicare databases for 1991 to 1999 studied the outcomes in almost 19,000 patients over 65 years of age with stage I or II non-small cell lung cancer (NSCLC) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/65\">",
"       65",
"      </a>",
"      ]. Multivariate analysis revealed that both lung cancer-specific survival and overall survival were significantly better in women in all treatment groups (surgery with or without additional postoperative treatment, RT or chemotherapy without surgery, or untreated), with hazard ratios (HRs) of 0.72 to 0.78. Overall, these differences were reflected in a higher five-year survival rate in women (46 versus 38 percent in men).",
"     </li>",
"     <li>",
"      A meta-analysis that included 2349 patients from five randomized trials evaluating contemporary, platinum-based chemotherapy regimens found that women had a longer overall survival than men (median 9.6 versus 8.6 months, hazard ratio [HR] 0.86, 95% CI 0.78-0.95) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/68\">",
"       68",
"      </a>",
"      ]. A significant difference was limited to patients with adenocarcinoma (median 10.9 versus 8.4 months, HR 0.70, 95% CI 0.59-0.83); the difference was not significant in patients with nonadenocarcinoma (survival 8.8 versus 8.5 months, HR 0.97, 95% CI 0.85-1.10).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Endocrine factors may also affect the natural history of disease in women who develop non-small cell lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/41,44\">",
"     41,44",
"    </a>",
"    ]. In the Women's Health Initiative trial, women on combined estrogen-progestin therapy had a significantly shorter survival compared to those given placebo (median survival 9.4 versus 16.1 months, hazard ratio 1.59) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. These findings are consistent with the hypothesis that endocrine factors either accelerate the transition of a preneoplastic lesion to an overt malignancy or promote tumor growth once a malignancy is evident.",
"   </p>",
"   <p>",
"    Although these data require confirmation, discontinuation of postmenopausal hormone therapy should be considered in women diagnosed with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gender-related differences in lung cancer gene mutations (eg, EGFR mutations) may also explain some of the treatment outcome disparities between women and men. Female gender is a significant clinical prognostic factor for patients treated with epidermal growth factor receptor tyrosine kinase inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solving the problem of lung cancer in women has three major components: prevention, early detection, and improved methods of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective intervention will be to stop people from smoking altogether, since approximately 90 percent of lung cancer cases are attributable to smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/70\">",
"     70",
"    </a>",
"    ]. Convincing individuals to stop smoking, however, is not an easy task. Smoking rates remain unacceptably high despite the overwhelming evidence that smoking causes lung cancer as well as other fatal health problems. In the US in 2006, smoking prevalence was about 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of smoking is disproportionately high among young girls and the less educated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/15,71\">",
"     15,71",
"    </a>",
"    ]. Currently, more young women than young men smoke; there is also a higher rate of smoking initiation and a lower rate of smoking cessation among women compared to men [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Although antismoking campaigns should be directed at the public-at-large, special emphasis should be targeted to young girls and the less educated. Unfortunately, these very subgroups are the preferential targets of tobacco advertisements [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/71,74-76\">",
"     71,74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The study of other methods of lung cancer prevention, including the role of diet and vitamins, should also be pursued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Early detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer survival rates are the highest for patients who present with early stages of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/77\">",
"     77",
"    </a>",
"    ]. For the lung cancer cases that we cannot prevent, it seems logical that it would be beneficial to diagnose them at as early a stage as possible. However, the role of screening for lung cancer remains unproven and controversial, and screening is not currently recommended.",
"   </p>",
"   <p>",
"    Eleven prospective studies of lung cancer screening using chest radiographs with or without sputum analysis have been performed, none of which demonstrated a significant benefit for screening [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/78-89\">",
"     78-89",
"    </a>",
"    ]. Furthermore, women were included in only two of these studies.",
"   </p>",
"   <p>",
"    Currently, there are several ongoing prospective screening trials employing both chest radiographs and chest CT scans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/90-100\">",
"     90-100",
"    </a>",
"    ]. In the National Lung Screening Trial, annual screening with CT for three years was shown to decrease overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/101\">",
"     101",
"    </a>",
"    ]. The results of this trial are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=see_link\">",
"     \"Screening for lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Improvements in treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Great efforts are currently being employed toward improving the treatment of lung cancer. Preclinical and clinical trials should continue to be supported, and gender should be addressed as a specific research variable. Women should be actively recruited for enrollment in lung cancer clinical trials, rather than excluding them, which was common in the past [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/13,48,102\">",
"     13,48,102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer has reached epidemic proportions in women, and it is now the leading cancer killer in women as well as men. In 2013, lung cancer is expected to take the lives of about 72,220 women in the United States compared with over 39,600 deaths due to breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10072/abstract/2\">",
"     2",
"    </a>",
"    ]. The vast majority of lung cancer cases are attributable to smoking, and smoking prevalence rates in women are expected to rise slowly into the next millennium.",
"   </p>",
"   <p>",
"    It is unresolved whether etiologic factors contributing to lung cancer differ in women and men, but there do appear to be some distinctions. The magnitude of the effect of smoking on the risk of developing the disease may not be different across the genders, but smoking appears to have an impact on the histology of lung cancer.",
"   </p>",
"   <p>",
"    Finally, although the evidence is not entirely clear, endocrine factors may influence both the development of lung cancer and its subsequent natural history. Consideration should be given to discontinuing postmenopausal HT in women diagnosed with lung cancer.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/3\">",
"      Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/4\">",
"      Gasperino J, Rom WN. Gender and lung cancer. Clin Lung Cancer 2004; 5:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/5\">",
"      Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 2005; 128:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/6\">",
"      Pauk N, Kub&iacute;k A, Zatloukal P, Krepela E. Lung cancer in women. Lung Cancer 2005; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/7\">",
"      Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/8\">",
"      Didkowska J, Manczuk M, McNeill A, et al. Lung cancer mortality at ages 35-54 in the European Union: ecological study of evolving tobacco epidemics. BMJ 2005; 331:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/9\">",
"      Shibuya K, Inoue M, Lopez AD. Statistical modeling and projections of lung cancer mortality in 4 industrialized countries. Int J Cancer 2005; 117:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/10\">",
"      Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/11\">",
"      Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 2005; 127:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/12\">",
"      Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/13\">",
"      Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91:675.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Department of Health and Human Services (USDHHS). The Health Consequences of Smoking: A Report of the Surgeon General. Public Health Service, Centers for Disease Control, Washington, DC 2004. CDC Publication No. 7829.",
"    </li>",
"    <li>",
"     Chollat-Traquet C. Women and Tobacco, World Health Organization, Geneva 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Tobacco use--United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999; 48:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/17\">",
"      Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults--United States, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/18\">",
"      Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993; 138:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/19\">",
"      Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol 1993; 22:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/20\">",
"      Zang EA, Wynder EL. Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers. Cancer 1992; 70:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/21\">",
"      Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J Natl Cancer Inst 1977; 58:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/22\">",
"      Schoenberg JB, Wilcox HB, Mason TJ, et al. Variation in smoking-related lung cancer risk among New Jersey women. Am J Epidemiol 1989; 130:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/23\">",
"      Osann KE. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res 1991; 51:4893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/24\">",
"      Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993; 54:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/25\">",
"      Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004; 96:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/26\">",
"      Taubes G. Claim of higher risk for women smokers attacked. Science 1993; 262:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/27\">",
"      Grivaux M, Breton JL, Bombaron P, et al. Lung cancer among women in France. Analysis of the 904 French women with lung cancer included in the KBP-2000-CPHG study of the French College of General Hospital-based Pneumologists (CPHG). Lung Cancer 2004; 45:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/28\">",
"      Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/29\">",
"      Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007; 168:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/30\">",
"      Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/31\">",
"      van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/32\">",
"      Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/33\">",
"      Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008; 26:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/34\">",
"      Schabath MB, Wu X, Vassilopoulou-Sellin R, et al. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 2004; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/35\">",
"      Blackman JA, Coogan PF, Rosenberg L, et al. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 2002; 11:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/36\">",
"      Kreuzer M, Gerken M, Heinrich J, et al. Hormonal factors and risk of lung cancer among women? Int J Epidemiol 2003; 32:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/37\">",
"      Chen KY, Hsiao CF, Chang GC, et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer 2007; 110:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/38\">",
"      Schwartz AG, Wenzlaff AS, Prysak GM, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 2007; 25:5785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/39\">",
"      Taioli E, Wynder EL. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 1994; 86:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/40\">",
"      Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/41\">",
"      Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/42\">",
"      Slatore CG, Chien JW, Au DH, et al. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010; 28:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/43\">",
"      Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 2010; 102:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/44\">",
"      Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/45\">",
"      Horwitz RI, Smaldone LF, Viscoli CM. An ecogenetic hypothesis for lung cancer in women. Arch Intern Med 1988; 148:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/46\">",
"      Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995; 141:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/47\">",
"      Alavanja MC, Brownson RC, Boice JD Jr, Hock E. Preexisting lung disease and lung cancer among nonsmoking women. Am J Epidemiol 1992; 136:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/48\">",
"      The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/49\">",
"      Menkes MS, Comstock GW, Vuilleumier JP, et al. Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. N Engl J Med 1986; 315:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/50\">",
"      Steinmetz KA, Potter JD, Folsom AR. Vegetables, fruit, and lung cancer in the Iowa Women's Health Study. Cancer Res 1993; 53:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/51\">",
"      Wu AH, Henderson BE, Pike MC, Yu MC. Smoking and other risk factors for lung cancer in women. J Natl Cancer Inst 1985; 74:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/52\">",
"      Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer 2008; 113:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/53\">",
"      de Perrot M, Licker M, Bouchardy C, et al. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2000; 119:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/54\">",
"      Ferguson MK, Wang J, Hoffman PC, et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann Thorac Surg 2000; 69:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/55\">",
"      Minami H, Yoshimura M, Miyamoto Y, et al. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 2000; 118:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/56\">",
"      Lienert T, Serke M, Sch&ouml;nfeld N, Loddenkemper R. Lung cancer in young females. Eur Respir J 2000; 16:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/57\">",
"      Ringer G, Smith JM, Engel AM, et al. Influence of sex on lung cancer histology, stage, and survival in a midwestern United States tumor registry. Clin Lung Cancer 2005; 7:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/58\">",
"      Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/59\">",
"      Silverberg E. Cancer statistics, 1980. CA Cancer J Clin 1980; 30:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/60\">",
"      Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 1992; 3:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/61\">",
"      Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 1999; 91:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/62\">",
"      Bignall JR, Martin M. Survival experience of women with bronchial carcinoma. Lancet 1972; 2:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/63\">",
"      Harley HR. Cancer of the lung in women. Thorax 1976; 31:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/64\">",
"      Kirsh MM, Tashian J, Sloan H. Carcinoma of the lung in women. Ann Thorac Surg 1982; 34:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/65\">",
"      Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol 2007; 25:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/66\">",
"      Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006; 130:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/67\">",
"      Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009; 4:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/68\">",
"      Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol 2010; 21:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/69\">",
"      Siegfried JM. Hormone replacement therapy and decreased lung cancer survival. J Clin Oncol 2006; 24:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/70\">",
"      Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003; 123:21S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/71\">",
"      Fielding JE. Smoking and women: tragedy of the majority. N Engl J Med 1987; 317:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/72\">",
"      Fiore MC. Trends in cigarette smoking in the United States. The epidemiology of tobacco use. Med Clin North Am 1992; 76:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/73\">",
"      Albright CL, Altman DG, Slater MD, Maccoby N. Cigarette advertisements in magazines: evidence for a differential focus on women's and youth magazines. Health Educ Q 1988; 15:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/74\">",
"      Warner KE, Goldenhar LM, McLaughlin CG. Cigarette advertising and magazine coverage of the hazards of smoking. A statistical analysis. N Engl J Med 1992; 326:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/75\">",
"      Mountain CF. Assessment of the role of surgery for control of lung cancer. Ann Thorac Surg 1977; 24:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/76\">",
"      Pierce JP, Lee L, Gilpin EA. Smoking initiation by adolescent girls, 1944 through 1988. An association with targeted advertising. JAMA 1994; 271:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/77\">",
"      Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/78\">",
"      Nash FA, Morgan JM, Tomkins JG. South London Lung Cancer Study. Br Med J 1968; 2:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/79\">",
"      An evaluation of radiologic and cytologic screening for the early detection of lung cancer: a cooperative pilot study of the American Cancer Society and the Veterans Administration. Cancer Res 1966; 26:2083.",
"     </a>",
"    </li>",
"    <li>",
"     Hayata Y, Funatsu H, Kato H, et al. Results of lung cancer screening programs in Japan. In: Early Detection and Localization of Lung Tumors in High Risk Groups: Recent Results of Cancer Research, Band PR (Ed), Springer, Berlin 1982. p.179.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/81\">",
"      Brett GZ. Earlier diagnosis and survival in lung cancer. Br Med J 1969; 4:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/82\">",
"      Wilde J. A 10 year follow-up of semi-annual screening for early detection of lung cancer in the Erfurt County, GDR. Eur Respir J 1989; 2:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/83\">",
"      Friedman GD, Collen MF, Fireman BH. Multiphasic Health Checkup Evaluation: a 16-year follow-up. J Chronic Dis 1986; 39:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/84\">",
"      Fontana RS, Sanderson DR, Woolner LB, et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991; 67:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/85\">",
"      Screening (lung cancer). Chest 1986; 89:324S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/86\">",
"      Kubik A, Parkin DM, Khlat M, et al. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/87\">",
"      Melamed MR, Flehinger BJ. Screening for lung cancer. Chest 1984; 86:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/88\">",
"      Flehinger BJ, Melamed MR. Current status of screening for lung cancer. Chest Surg Clin N Am 1994; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/89\">",
"      Patterson WB, Emanuel EJ. The eligibility of women for clinical research trials. J Clin Oncol 1995; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/90\">",
"      Oken MM, Marcus PM, Hu P, et al. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst 2005; 97:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/91\">",
"      Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/92\">",
"      International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/93\">",
"      Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005; 235:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/94\">",
"      Sone S, Li F, Yang ZG, et al. Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001; 84:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/95\">",
"      Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002; 222:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/96\">",
"      MacRedmond R, Logan PM, Lee M, et al. Screening for lung cancer using low dose CT scanning. Thorax 2004; 59:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/97\">",
"      Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003; 362:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/98\">",
"      Novello S, Fava C, Borasio P, et al. Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers. Ann Oncol 2005; 16:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/99\">",
"      Gohagan J, Marcus P, Fagerstrom R, et al. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004; 126:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/100\">",
"      van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007; 120:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/101\">",
"      National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10072/abstract/102\">",
"      Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. N Engl J Med 1986; 315:1377.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1431 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10072=[""].join("\n");
var outline_f9_53_10072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Comparison of men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H953397484\">",
"      Air pollution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endocrine factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Early detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Improvements in treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/1431\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1431|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/35/22077\" title=\"figure 1\">",
"      Lung cancer death rate women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/58/5038\" title=\"figure 2\">",
"      Trends in cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1431|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/2/12331\" title=\"table 1\">",
"      Cancer deaths in women 1996",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12394?source=related_link\">",
"      Lung cancer in never smokers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28586?source=related_link\">",
"      Screening for lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10073="The child with tall stature or abnormally rapid growth";
var content_f9_53_10073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The child with tall stature or abnormally rapid growth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10073/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10073/contributors\">",
"     Erick J Richmond, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10073/contributors\">",
"     Alan D Rogol, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10073/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10073/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10073/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/53/10073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statural growth, a fundamental characteristic of childhood, is a complex process that is determined by the interaction of genetics, nutrition, and socioeconomic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/1\">",
"     1",
"    </a>",
"    ]. Regular assessment of growth is an essential part of pediatric practice. The importance of comparing a child's growth pattern to established norms cannot be overemphasized. Because growth is an active process, growth velocity charts are more useful than are standard (distance) growth charts in determining the normality of growth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/2\">",
"     2",
"    </a>",
"    ]. However, in interpreting a child's growth velocity, allowance must be made for age, pubertal development, and other factors. &nbsp;",
"   </p>",
"   <p>",
"    The causes, diagnosis, and treatment of children with abnormally rapid growth and tall stature will be reviewed here. The evaluation of children with short stature is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before considering abnormal growth, one should understand normal growth and development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=see_link&amp;anchor=H8#H8\">",
"     \"Normal growth patterns in infants and prepubertal children\", section on 'Linear growth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Growth velocity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both boys and girls, peak growth velocity occurs during the fourth month of intrauterine life, reaching 2.5",
"    <span class=\"nowrap\">",
"     cm/week",
"    </span>",
"    (130",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/3\">",
"     3",
"    </a>",
"    ], followed by a slowing until birth. In the first year of life, linear growth remains rapid; approximately 25 cm is gained. The rate of growth declines, and the average gain is 12.5",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    between the first and the second year, 7",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    between ages two and four, 6",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    between ages four and six, and then 5.5",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    until puberty.",
"   </p>",
"   <p>",
"    The second acceleration in height velocity takes place at puberty. Girls have their peak height velocity (mean 9",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    during early puberty (Tanner stages II to III) (",
"    <a class=\"graphic graphic_figure graphicRef74573 \" href=\"UTD.htm?16/0/16387\">",
"     figure 1A",
"    </a>",
"    ), whereas boys reach their peak height velocity (mean, 10.3",
"    <span class=\"nowrap\">",
"     cm/year)",
"    </span>",
"    during mid-puberty (Tanner stages III to IV) (",
"    <a class=\"graphic graphic_figure graphicRef66909 \" href=\"UTD.htm?4/37/4692\">",
"     figure 1B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. After the pubertal growth spurt, growth velocity diminishes toward zero as the epiphyses of the long bones fuse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These growth velocities are average velocities (50th percentile) based upon the Tanner height velocity charts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As a result, pediatricians must expect that children who are growing normally follow a curve between the third and 97th percentile, not necessarily the 50th percentile.",
"   </p>",
"   <p>",
"    Somatic growth and biologic maturation are influenced by several factors that act independently or in concert to modify a child's genetic growth potential. Size at birth is determined more by maternal nutrition and intrauterine and placental factors than by genetic constitution. The correlation coefficient between birth length and adult height is only 0.25, whereas that between height at two years and adult height is 0.80 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/7\">",
"     7",
"    </a>",
"    ]. All the genes that affect growth may not be expressed at birth; as a result, the correlation between the size of the child and that of the parents is weak during the first year of life but rises to 0.50 by about 18 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bone age and prediction of height potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone age is a measure of skeletal maturity, generally obtained by assessing the appearance and shape of the bones of the hand and wrist from a radiograph. The methods used most commonly for determining bone age are the Greulich and Pyle Atlas [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/9\">",
"     9",
"    </a>",
"    ] and the Tanner-Whitehouse (TW2) method [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended technique for predicting height in children with tall stature is that developed by Bayley-Pinneau [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], which compares the hand-wrist radiograph with the bone age atlas developed by Greulich and Pyle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/9\">",
"     9",
"    </a>",
"    ]. The bone age corresponds to a percentage of adult height, which is shown on a table. To predict adult height, the present height is multiplied by 100 and divided by percent adult height. Prediction of height plays a key role in the decision about therapeutic intervention in tall stature. Predicting adult height is more accurate in tall girls than in boys, and for both sexes, the prediction becomes increasingly accurate with advancing age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/13\">",
"     13",
"    </a>",
"    ]. Nonetheless, for any individual the height prediction lacks precision, as reflected by a broad 95 percent confidence interval.",
"   </p>",
"   <p>",
"    The mid-parental target height is sometimes used as a first approximation of a child's adult height, but is substantially less accurate than the bone-age method described above, because it does not reflect environmental contributions to growth or disease processes. It is calculated from the heights of both parents and the child's gender (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?30/3/30769?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=see_link&amp;anchor=H11#H11\">",
"     \"Normal growth patterns in infants and prepubertal children\", section on 'Predicted height'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ABNORMALLY RAPID GROWTH VELOCITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremes of growth can be defined based upon the normal variance of growth within the reference population. In general, a child whose height differs by more than 2 standard deviations (SD) from the population mean is considered either too tall or too short. This threshold is equivalent to a z-score of +2.0 (&gt;97.5 percentile) for tall stature, or a z-score of -2.0 (&lt;2.5 percentile) for short stature. Less stringent definitions of tall and short stature use thresholds of &gt;95th percentile and &lt;5th percentile respectively.",
"   </p>",
"   <p>",
"    Percentiles and z-scores can be calculated using a calculator for recumbent length (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34339?source=see_link\">",
"     calculator 2",
"    </a>",
"    ), or standing height for boys (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=see_link\">",
"     calculator 3",
"    </a>",
"    ) or for girls (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=see_link\">",
"     calculator 4",
"    </a>",
"    ). Alternatively, percentiles can be estimated by plotting growth velocity on a standard chart (",
"    <a class=\"graphic graphic_figure graphicRef74573 graphicRef66909 \" href=\"UTD.htm?32/43/33464\">",
"     figure 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although tall stature is almost as common as is short stature, few children or their families seek medical attention, presumably because tall stature is socially acceptable and may be advantageous. It should be emphasized that most children who grow excessively are part of a continuum of a normal distribution curve, and only a minority will have a defined abnormality of growth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/14\">",
"     14",
"    </a>",
"    ]. Nevertheless, it is critical to be able to identify situations in which tall stature or an accelerated growth rate provides a clue to an underlying disorder (",
"    <a class=\"graphic graphic_table graphicRef64123 \" href=\"UTD.htm?3/7/3196\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Determining the heights of the biological parents is of critical importance because their height reflects the genetic component for growth and development of the child. The parents' heights should be measured using a stadiometer, if possible, rather than by history or estimation. The child's pattern of growth, medical history (including detailed family history), and physical examination remain the mainstays of assessment of tall or rapidly growing children. When dysmorphic features are found, special effort should be made to rule out the disorders and syndromes that are associated with excessive growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STATURAL OVERGROWTH IN INFANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated growth occurring during fetal life and infancy has several causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Maternal diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal diabetes mellitus is the most common cause of large-for-gestational age infants. Maternal hyperglycemia leads to fetal hyperglycemia, which in turn causes fetal hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/15\">",
"     15",
"    </a>",
"    ]. The hyperinsulinemia results in increased fetal growth, an increase in subcutaneous tissue, and enlargement of most organs, including the liver. These infants usually are large, more so in weight than in length [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/16\">",
"     16",
"    </a>",
"    ]. Because of hyperinsulinemia, infants of diabetic mothers should be monitored for hypoglycemia during the first hours and days of life [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/17\">",
"     17",
"    </a>",
"    ]. The hyperinsulinemia is transient and should not in itself cause overgrowth in infancy or childhood, although there is an association between macrosomia at birth and later development of obesity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cerebral gigantism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with cerebral gigantism (Sotos syndrome) tend to be large at birth and continue to grow rapidly during the early years of childhood. Puberty usually occurs early in these children, resulting in premature epiphyseal fusion and, hence, adult height is normal in many of these children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Thus, intervention usually is not needed. Distinctive dysmorphic features include macrocephaly, high forehead, frontal bossing, hypertelorism, prominent jaw, high arched palate, intellectual disability (mental retardation), and poor coordination. Growth hormone secretion and serum insulin-like growth factor-1 (IGF-1) concentrations are normal.",
"   </p>",
"   <p>",
"    The syndrome is sporadic in most cases, although some familial cases segregating in an autosomal dominant pattern have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/20\">",
"     20",
"    </a>",
"    ]. Mutations of the NSD1 gene have been identified in the majority of individuals with Sotos syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=see_link&amp;anchor=H12329086#H12329086\">",
"     \"Microdeletion syndromes (chromosomes 1 to 11)\", section on '5q35 deletion syndrome (Sotos syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Beckwith-Wiedemann syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with the Beckwith-Wiedemann syndrome have a growth pattern similar to that of children with cerebral gigantism, without an increase in adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/21\">",
"     21",
"    </a>",
"    ]. They characteristically have macrosomia, including visceromegaly and macroglossia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/16\">",
"     16",
"    </a>",
"    ]. Other clinical features include omphalocele, prominent occiput, and hypoglycemia with hyperinsulinism, renal abnormalities, hemihypertrophy, and a risk for embryonal tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/22\">",
"     22",
"    </a>",
"    ]. Over-expression of insulin-like growth factor 2 (IGF-2) is probably an important determinant of the phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=see_link\">",
"     \"Beckwith-Wiedemann syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STATURAL OVERGROWTH IN CHILDHOOD AND ADOLESCENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated growth occurring in childhood or adolescence can result from both endocrine and nonendocrine disorders. The former can involve hormone excess, deficiency, or resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Precocious puberty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual precocity is more common in girls than boys. It can be central (gonadotropin-releasing hormone [GnRH]-dependent) or peripheral (GnRH-independent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/24\">",
"     24",
"    </a>",
"    ]. In both cases, linear growth is accelerated during childhood, often with markedly advanced bone maturation. This results in the paradox of the tall child who, because of very early epiphyseal closure, will be short as an adult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Central precocious puberty is either idiopathic or secondary to a central nervous system abnormality. Causes of peripheral precocious puberty include congenital adrenal hyperplasia, virilizing adrenal, testicular and ovarian tumors, ovarian cysts, testotoxicosis, McCune-Albright syndrome, human chorionic gonadotropin-secreting tumors, and rarely, longstanding hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=see_link\">",
"     \"Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=see_link\">",
"     \"Ovarian cysts and neoplasms in infants, children, and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Growth hormone excess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive growth hormone secretion causes gigantism in growing children and acromegaly after fusion of the epiphyses, usually in adults. Although rare in children, the possibility of gigantism should be considered when the height exceeds +3 to +4 SD [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/9/13464?source=see_link\">",
"     \"Pituitary gigantism\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism caused by endogenous overproduction or overtreatment with exogenous thyroxine may lead to increased growth, advanced bone age, and in early life, craniosynostosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/26\">",
"     26",
"    </a>",
"    ]. The tall stature and transient increase in linear growth usually do not require intervention, and the growth rate normalizes with treatment of the hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=see_link\">",
"     \"Evaluation and management of neonatal Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sex hormone deficiency or insensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent hypogonadism, that is, permanent deficiency of testosterone in males or of estrogen in females, results in delayed skeletal maturation, a prolonged period of growth, tall stature, and eunuchoid proportions, with long legs, diminished upper-lower segment ratio, and low sitting height compared to height. As an example, several male patients with estrogen deficiency resulting from aromatase deficiency or estrogen resistance caused by a mutation of the estrogen receptor gene who were extremely tall have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link\">",
"     \"Causes of primary hypogonadism in males\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Familial glucocorticoid deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial glucocorticoid deficiency is a grouping of rare autosomal recessive disorders characterized by hypoglycemia, seizures, increased skin pigmentation, and in the type 1 form is also associated with tall stature or advanced bone age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Patients with the type 2 form are not typically tall [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/31\">",
"     31",
"    </a>",
"    ]. Biochemical findings in both forms include extremely high plasma corticotropin (ACTH) concentrations together with low or undetectable serum cortisol concentrations that do not respond to exogenous ACTH stimulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=see_link&amp;anchor=H8#H8\">",
"     \"Unusual causes of adrenal insufficiency\", section on 'Familial glucocorticoid deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excessive production of adrenal androgens probably is responsible for the tall stature. Another suggestion is that the high serum ACTH concentrations could activate melanocyte-stimulating hormone receptors in cartilaginous growth plates and that the increase in height is caused by the unopposed anabolic action of growth hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Familial glucocorticoid resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cortisol resistance is a rare cause of hypercortisolism, but may cause excessive growth because of the effects of the increased ACTH levels on adrenal androgen production. The disorder presents in females with hirsutism, male pattern baldness, menstrual abnormalities, and infertility, and presents in males with isosexual precocious puberty, abnormal spermatogenesis, and infertility. Because this is gonadotropin-independent precocity, the testes are relatively small compared to the degree of growth and virilization. The bone age is advanced and many quite tall boys do not become excessively tall adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=see_link&amp;anchor=H12#H12\">",
"     \"Unusual causes of adrenal insufficiency\", section on 'Familial glucocorticoid resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Congenital total lipodystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital total lipodystrophy is a rare autosomal recessive disorder. The main clinical features, in addition to overgrowth and acromegaloid changes, are generalized absence of subcutaneous fat, muscular hypertrophy, hyperpigmentation, enlargement of the penis or clitoris, advanced bone age, insulin resistance, hyperinsulinemia, hyperlipidemia, and nonketotic hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Large doses of insulin are given to avoid decompensation, but normoglycemia may not be attainable. Adult height in these patients tends to be normal or tall [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=see_link&amp;anchor=H3#H3\">",
"     \"Lipodystrophic syndromes\", section on 'Congenital generalized lipodystrophy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nonendocrine disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Exogenous obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity may be accompanied by modest overgrowth and early onset of puberty, especially in girls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/36\">",
"     36",
"    </a>",
"    ]. These children usually have diminished overall growth hormone production but high normal serum concentrations of IGF-binding proteins and IGF-I, typically leading to tall stature for age prior to puberty. However, bone age may be advanced, and puberty starts early, causing premature epiphyseal fusion. These adolescents often attain normal adult height unless puberty starts unusually early, in which case they may not reach their midparental target height [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"     \"Clinical evaluation of the obese child and adolescent\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Klinefelter syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Klinefelter syndrome is caused by an abnormality in chromosome number in which two or more X chromosomes are present in phenotype males. The most common abnormal karyotype is 47 XXY. Prepubertal boys often are tall for their age, with relatively long legs, and they may have learning disabilities, mainly in expressive language. Small testes and gynecomastia are the most common features on physical examination during adolescence. Other genital abnormalities such as small phallus, hypospadias, and cryptorchidism may be present. Almost all boys enter puberty, but there is marked heterogeneity in the degree of virilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of primary hypogonadism in males\", section on 'Klinefelter's syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=see_link\">",
"     \"Hypospadias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link&amp;anchor=H6#H6\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum luteinizing hormone and follicle-stimulating hormone concentrations are high in adolescents and adults with Klinefelter syndrome, although they are often normal until the onset of puberty. Usually, serum testosterone concentrations are in the low normal adult range. Testosterone treatment can be initiated during the pubertal years to facilitate development of secondary sexual characteristics and minimize the psychologic complications of hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/38\">",
"     38",
"    </a>",
"    ]. This approach also may diminish adult height.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     XYY syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Boys with a XYY karyotype have a tendency to tall stature and problems in motor and language development [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/39\">",
"     39",
"    </a>",
"    ]. Adults with this syndrome are tall, have nodular cystic acne, large teeth, radioulnar synostosis, tremor, incoordination, and sometimes antisocial behavior. No treatment for the tall stature is required, unless desired by the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Marfan syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marfan syndrome is an autosomal dominant abnormality of connective tissue characterized by tall stature, long thin fingers (arachnodactyly), hyperextension of joints, and lens subluxation, usually in the superior direction. Pectus excavatum, scoliosis, aortic or mitral regurgitation, and aortic root dilatation may be present. Female and male patients with this syndrome may attain excessively tall height, and treatment with estrogen in women and testosterone in men may be indicated, especially if any orthopedic problem is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The basic defect in Marfan syndrome has been traced to an altered fibrillin gene (FBN1) on chromosome 15q21.1 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Fibrillin is a connective tissue protein found in microfibrils, a constituent of elastic tissue; these microfibrils are abundant in affected tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Homocystinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homocystinuria is an inherited inborn error of methionine metabolism, caused by a deficiency of the enzyme cystathionine synthetase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/42\">",
"     42",
"    </a>",
"    ]. Some of the clinical features are similar to those of Marfan syndrome, with subluxation of the lens being the most consistent finding, although the direction of subluxation is usually downward. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=see_link&amp;anchor=H7#H7\">",
"     \"Ectopia lentis (dislocated lens) in children\", section on 'Systemic causes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fifty percent of patients with homocystinuria have intellectual disability (mental retardation). Life-threatening thromboembolic phenomena may occur at any age, and early onset of osteoporosis is seen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/43\">",
"     43",
"    </a>",
"    ]. No treatment for the tall stature is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Neurofibromatosis type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromatosis type 1 is an autosomal dominant disorder that comprises at least 85 percent of all cases of neurofibromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/44\">",
"     44",
"    </a>",
"    ]. It is caused by an abnormality of neural crest differentiation and migration during the early stages of embryogenesis. This disorder is linked to a gene on chromosome 17 that encodes a protein called neurofibromin, which restricts cell proliferation by activating GTP hydrolysis on ras proteins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short stature is common (as a result of precocious puberty), but rare patients are excessively tall who have otherwise unexplained dysregulated growth hormone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Thus, neurofibromatosis should be considered in patients with overgrowth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     FAMILIAL (CONSTITUTIONAL) TALL STATURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial (constitutional) tall stature, a variant of the normal pattern of childhood growth and development, is defined as a condition in which the height of an individual is 2 SD above the corresponding mean height for a normal subject of the same age and sex, in the absence of pathologic causes of tall stature [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Referrals for tall boys (otherwise normal) are very rare. Because tall women are more accepted in society than they were in the past, consultation to limit their adult height has become much less frequent. Usually the diagnosis is not difficult and is established by a family history of tall stature and lack of dysmorphic features, which permits distinction from the syndromes of excessive growth.",
"   </p>",
"   <p>",
"    In the evaluation of tall children, a careful family history, physical examination, and bone age frequently are all that are required for reassurance and support. Accurate measurements every 6 to 12 months help verify that these children have a high normal, but not excessive growth velocity. As noted previously, prediction of height using Bayley-Pinneau tables becomes more accurate in children older than 12 years of age. Use of these tables in younger children may overestimate adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Bone age and prediction of height potential'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Genetic factors play the most important roles in the pathogenesis of familial tall stature. Endocrinologic studies of tall children have yielded variable results. Growth hormone secretion and serum IGF-1 and IGF binding-protein-3 concentrations often are in the upper range of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/48\">",
"     48",
"    </a>",
"    ]. Both increased secretion of growth hormone and greater efficiency of growth-hormone-mediated IGF-1 production may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical treatment of children and adolescents with familial tall stature is controversial. Treatment was common in the past, particularly for girls, but is now strongly discouraged except in extreme cases. This is because of increased cultural acceptance of tall stature and recognition of side effects of treatment.",
"   </p>",
"   <p>",
"    Sex steroids have been used in the treatment of tall boys and girls since the late 1950s. The goal is to promote premature epiphyseal fusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Estrogen causes epiphyseal fusion in both girls and boys [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The effects of steroid hormones on bone maturation are caused by an indirect action mediated by the growth hormone-IGF-I axis, combined with a direct effect on the epiphyses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data presented below come from studies of children with familial tall stature, but they may be applicable to other causes of rapid growth in which the underlying disorder cannot be corrected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Psychosocial considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial problems in tall adolescent girls and boys have been recognized by pediatricians and endocrinologists, and it is these issues that influence the final decision about treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these considerations, dissatisfaction with treatment is common among girls who were treated for tall stature. In one study, more than 40 percent of treated women were dissatisfied with their (or their parent's) decision to assess and treat [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/56\">",
"     56",
"    </a>",
"    ]. Dissatisfaction was related to the patient not having an active role in the decision-making, negative experiences with the assessment or treatment procedures, side effects of therapy, or late side effects that women believed were associated with the therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For treatment of tall girls, estrogen, in the form of estradiol or ethinyl estradiol, was used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/57\">",
"     57",
"    </a>",
"    ]. Treatment was usually started when the patient's bone age was between 10 and 12 years, and always before a bone age of 14 to 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/13\">",
"     13",
"    </a>",
"    ]. The earlier the intervention, the more likely that adult height will be decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/13\">",
"     13",
"    </a>",
"    ]. Treatment was continued until the epiphyses fused, because posttreatment growth may be substantial if cessation is premature.",
"   </p>",
"   <p>",
"    The following considerations should guide treatment decisions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean adjusted height reduction after estrogen treatment varies from 1.1 to 2.4 cm, and ranges vary from -2.6 cm to 6.2 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/47\">",
"       47",
"      </a>",
"      ], significantly less than previously claimed [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Estrogen side effects include nausea, weight gain, edema, and hypertension; other potential problems, such as thromboembolism and endometrial hyperplasia, have not been definitely related to estrogen therapy in children but also should be discussed.",
"     </li>",
"     <li>",
"      Estrogen treatment during adolescence may have a negative impact on later fertility. This was illustrated in a study of 1243 adult women with hereditary tall stature, 310 of whom had been treated with estrogen as adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/58\">",
"       58",
"      </a>",
"      ]. After adjustment for age, those who had received estrogen had an increased risk of infertility (inability to conceive after 12 months of trying; RR 1.8, 95% CI 1.4-2.3) and had lower fecundity (40 percent less likely to conceive in any given menstrual cycle of unprotected intercourse) when compared to those who had not received estrogen therapy. There were no differences in the distribution of infertility diagnoses between the estrogen-treated and untreated groups, and the mechanism for the increase in risk is unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"       \"Overview of infertility\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgens also accelerate epiphyseal fusion, presumably via aromatization to estrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/14\">",
"     14",
"    </a>",
"    ]. Although testosterone can be given as treatment of constitutional tall stature in boys, its use is extremely uncommon. Usually, it is given in the form of a long-acting intramuscular testosterone ester, mean dose 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per month. In clinical practice, 500 mg every two weeks or 250 mg once a week are used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/14\">",
"     14",
"    </a>",
"    ]. It is more effective when started when the bone age is less than 14 to 15 years of age and can increase growth if started at older bone ages [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10073/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In addition to measurement of height, assessment of growth velocity is important to the assessment of a child with tall stature. Growth velocity in healthy children varies with age, gender, and pubertal status; growth velocity percentiles can be estimated by plotting on a standard chart (",
"      <a class=\"graphic graphic_figure graphicRef74573 graphicRef66909 \" href=\"UTD.htm?32/43/33464\">",
"       figure 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Growth velocity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation for tall stature should also include radiographic determination of bone age, and this result is used to predict height potential. Height potential can also be estimated from the heights of the child's parents, but this method is substantially less accurate. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Bone age and prediction of height potential'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of a disorder causing rapid growth should be considered in children with one or more of the following characteristics (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Abnormally rapid growth velocity'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Growth velocity that is greater than the 75th percentile",
"     </li>",
"     <li>",
"      Any child with rapid growth and features suggestive of these disorders, including dysmorphic features",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of abnormally rapid growth during infancy include maternal diabetes mellitus, cerebral gigantism (Sotos syndrome), and Beckwith-Wiedemann syndrome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Statural overgrowth in infancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endocrine causes of abnormally rapid growth during childhood and adolescence include precocious puberty, growth hormone excess (pituitary gigantism), hyperthyroidism, virilizing congenital adrenal hyperplasia, and familial glucocorticoid deficiency or resistance (",
"      <a class=\"graphic graphic_table graphicRef64123 \" href=\"UTD.htm?3/7/3196\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Statural overgrowth in childhood and adolescence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial (constitutional) tall stature, a variant of the normal pattern of childhood growth and development, is defined as a condition in which the height of an individual is more than 2 SD above the corresponding mean height for a normal subject of the same age and gender. Distinguishing features are a family history of tall stature and lack of dysmorphism or other clinical features suggesting pathologic causes of abnormally rapid growth. Medical treatment for familial tall stature is very controversial, and is generally discouraged except in extreme cases. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Familial (constitutional) tall stature'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Reiter EO, Rosenfeld RG. Normal and aberrant growth. In: Williams Textbook of Endocrinology, Wilson JD, Foster DW, Kronenberg HM, Larsen PR (Eds), Saunders, Philadelphia 1998. p.1427.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/2\">",
"      Brook CG, Hindmarsh PC, Healy MJ. A better way to detect growth failure. Br Med J (Clin Res Ed) 1986; 293:1186.",
"     </a>",
"    </li>",
"    <li>",
"     Lifshitz F, Cervantes CD. Short stature. In: Pediatric Endocrinology, Lifshitz F (Ed), Marcel Dekker, New York 1996. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/4\">",
"      Tanner JM, Whitehouse RH, Takaishi M. Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II. Arch Dis Child 1966; 41:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/5\">",
"      Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51:170.",
"     </a>",
"    </li>",
"    <li>",
"     Styne D. Growth. In: Basic and Clinical Endocrinology, Greenspan FS, Strewler GJ (Eds), Appleton and Lange, Connecticut 1997. p.157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/7\">",
"      HEALY MJ, LOCKHART RD, MACKENZIE JD, et al. Aberdeen growth study. I. The prediction of adult body measurements from measurements taken each year from birth to 5 years. Arch Dis Child 1956; 31:372.",
"     </a>",
"    </li>",
"    <li>",
"     Tanner JM. Fetus into Man: Physical Growth from Conception to Maturity, Harvard University Press, Cambridge 1989.",
"    </li>",
"    <li>",
"     Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, Stanford University Press, Stanford 1950.",
"    </li>",
"    <li>",
"     Tanner JM, Whitehouse RH, Cameron N, et al. Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method), Academic Press, London 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/11\">",
"      BAYLEY N, PINNEAU SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952; 40:423.",
"     </a>",
"    </li>",
"    <li>",
"     Hochberg Z, Ritzen M. Tall Stature. In: Practical Algorithms in Pediatric Endocrinology, Hochberg Z (Ed), Karger, Basel, Switzerland 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/13\">",
"      de Waal WJ, Greyn-Fokker MH, Stijnen T, et al. Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children. J Clin Endocrinol Metab 1996; 81:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/14\">",
"      Drop SL, De Waal WJ, De Muinck Keizer-Schrama SM. Sex steroid treatment of constitutionally tall stature. Endocr Rev 1998; 19:540.",
"     </a>",
"    </li>",
"    <li>",
"     Mercurio MR, Ehrenkranz RA. Infants of diabetic mothers. In: Therapy for Diabetes Mellitus and Related Disorders, Lebovitz HE (Ed), American Diabetes Association, Alexandria 1998.",
"    </li>",
"    <li>",
"     Blizzard RM, Johanson A. Disorders of growth. In: The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence, Kappy MS, Blizzard RM, Migeon CJ (Eds), Thomas, Illinois 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/17\">",
"      Barnes-Powell LL. Infants of diabetic mothers: the effects of hyperglycemia on the fetus and neonate. Neonatal Netw 2007; 26:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/18\">",
"      Sotos JF, Cutler EA, Dodre P. Cerebral gigantism. Am J Dis Child 1977; 131:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/19\">",
"      Agwu JC, Shaw NJ, Kirk J, et al. Growth in Sotos syndrome. Arch Dis Child 1999; 80:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/20\">",
"      Cole TR, Hughes HE. Sotos syndrome: a study of the diagnostic criteria and natural history. J Med Genet 1994; 31:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/21\">",
"      Weng EY, Moeschler JB, Graham JM Jr. Longitudinal observations on 15 children with Wiedemann-Beckwith syndrome. Am J Med Genet 1995; 56:366.",
"     </a>",
"    </li>",
"    <li>",
"     Shuman C, Smith AC, Weksberg R. Beckwith-Wiedemann Syndrome. GeneReviews, 2008. file://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=bws (Accessed on April 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/23\">",
"      Choufani S, Shuman C, Weksberg R. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet 2010; 154C:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/24\">",
"      Klein KO. Precocious puberty: who has it? Who should be treated? J Clin Endocrinol Metab 1999; 84:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/25\">",
"      Sotos JF. Overgrowth. Hormonal Causes. Clin Pediatr (Phila) 1996; 35:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/26\">",
"      Schlesinger S, MacGillivray MH, Munschauer RW. Acceleration of growth and bone maturation in childhood thyrotoxicosis. J Pediatr 1973; 83:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/27\">",
"      Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/28\">",
"      Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/29\">",
"      Thistlethwaite D, Darling JA, Fraser R, et al. Familial glucocorticoid deficiency. Studies of diagnosis and pathogenesis. Arch Dis Child 1975; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/30\">",
"      Coulter JB, Diver MJ, Isherwood DM, et al. Tall stature in isolated glucocorticoid deficiency: A case report and review of the literature. J Pediatr Endocrinol 1991; 4:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/31\">",
"      Chung TT, Chan LF, Metherell LA, Clark AJ. Phenotypic characteristics of familial glucocorticoid deficiency (FGD) type 1 and 2. Clin Endocrinol (Oxf) 2010; 72:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/32\">",
"      van Rossum EF, Lamberts SW. Glucocorticoid resistance syndrome: A diagnostic and therapeutic approach. Best Pract Res Clin Endocrinol Metab 2006; 20:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/33\">",
"      SEIP M. Lipodystrophy and gigantism with associated endocrine manifestations. A new diencephalic syndrome? Acta Paediatr 1959; 48:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/34\">",
"      Huseman C, Johanson A, Varma M, Blizzard RM. Congenital lipodystrophy: An endocrine study in three siblings. I. Disorders of carbohydrate metabolism. J Pediatr 1978; 93:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/35\">",
"      Garg A, Agarwal AK. Lipodystrophies: disorders of adipose tissue biology. Biochim Biophys Acta 2009; 1791:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/36\">",
"      Forbes GB. Nutrition and growth. J Pediatr 1977; 91:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/37\">",
"      Biro FM, Khoury P, Morrison JA. Influence of obesity on timing of puberty. Int J Androl 2006; 29:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/38\">",
"      Sotos JF. Genetic disorders associated with overgrowth. Clin Pediatr (Phila) 1997; 36:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/39\">",
"      Robinson A, Lubs HA, Nielsen J, S&oslash;rensen K. Summary of clinical findings: profiles of children with 47,XXY, 47,XXX and 47,XYY karyotypes. Birth Defects Orig Artic Ser 1979; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/40\">",
"      Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991; 352:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/41\">",
"      Hayward C, Porteous ME, Brock DJ. Mutation screening of all 65 exons of the fibrillin-1 gene in 60 patients with Marfan syndrome: report of 12 novel mutations. Hum Mutat 1997; 10:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/42\">",
"      Fowler B, Jakobs C. Post- and prenatal diagnostic methods for the homocystinurias. Eur J Pediatr 1998; 157 Suppl 2:S88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/43\">",
"      Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/44\">",
"      Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/45\">",
"      Carmi D, Shohat M, Metzker A, Dickerman Z. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics 1999; 103:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/46\">",
"      Josefson J, Listernick R, Fangusaro JR, et al. Growth hormone excess in children with neurofibromatosis type 1-associated and sporadic optic pathway tumors. J Pediatr 2011; 158:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/47\">",
"      Joss EE, Temperli R, Mullis PE. Adult height in constitutionally tall stature: accuracy of five different height prediction methods. Arch Dis Child 1992; 67:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/48\">",
"      Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993; 76:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/49\">",
"      Tauber M, Pienkowski C, Rochiccioli P. Growth hormone secretion in children and adolescents with familial tall stature. Eur J Pediatr 1994; 153:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/50\">",
"      Bierich JR. Estrogen treatment of girls with constitutional tall stature. Pediatrics 1978; 62:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/51\">",
"      Sorgo W, Scholler K, Heinze F, et al. Critical analysis of height reduction in oestrogen-treated tall girls. Eur J Pediatr 1984; 142:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/52\">",
"      Frank GR. The role of estrogen in pubertal skeletal physiology: epiphyseal maturation and mineralization of the skeleton. Acta Paediatr 1995; 84:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/53\">",
"      Wettenhall HN, Cahill C, Roche AF. Tall girls: a survey of 15 years of management and treatment. J Pediatr 1975; 86:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/54\">",
"      Prader A, Zachmann M. Treatment of excessively tall girls and boys with sex hormones. Pediatrics 1978; 62:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/55\">",
"      Bailey JD, Park E, Cowell C. Estrogen treatment of girls and constitutional tall stature. Pediatr Clin North Am 1981; 28:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/56\">",
"      Pyett P, Rayner J, Venn A, et al. Using hormone treatment to reduce the adult height of tall girls: are women satisfied with the decision in later years? Soc Sci Med 2005; 61:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/57\">",
"      Zachmann M, Ferrandez A, M��rset G, Prader A. Estrogen treatment of excessively tall girls. Helv Paediatr Acta 1975; 30:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10073/abstract/58\">",
"      Venn A, Bruinsma F, Werther G, et al. Oestrogen treatment to reduce the adult height of tall girls: long-term effects on fertility. Lancet 2004; 364:1513.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5848 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10073=[""].join("\n");
var outline_f9_53_10073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL GROWTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Growth velocity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bone age and prediction of height potential",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ABNORMALLY RAPID GROWTH VELOCITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STATURAL OVERGROWTH IN INFANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Maternal diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cerebral gigantism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STATURAL OVERGROWTH IN CHILDHOOD AND ADOLESCENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Growth hormone excess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sex hormone deficiency or insensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Familial glucocorticoid deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Familial glucocorticoid resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Congenital total lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nonendocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Exogenous obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Klinefelter syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - XYY syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Homocystinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Neurofibromatosis type 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      FAMILIAL (CONSTITUTIONAL) TALL STATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Psychosocial considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Estrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Androgens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5848\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5848|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/0/16387\" title=\"figure 1A\">",
"      Height velocity in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/37/4692\" title=\"figure 1B\">",
"      Height velocity in boys",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5848|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/7/3196\" title=\"table 1\">",
"      Differential dx overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?30/3/30769?source=related_link\" title=\"calculator 1\">",
"      Calculator: Mid-parental target height prediction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?33/34/34339?source=related_link\" title=\"calculator 2\">",
"      Calculator: CDC/NCHS infant length for age percentiles (&lt;36 months)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/47/22262?source=related_link\" title=\"calculator 3\">",
"      Calculator: CDC height for age percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?22/7/22646?source=related_link\" title=\"calculator 4\">",
"      Calculator: CDC height for age percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24473?source=related_link\">",
"      Beckwith-Wiedemann syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30536?source=related_link\">",
"      Causes of primary hypogonadism in males",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=related_link\">",
"      Ectopia lentis (dislocated lens) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=related_link\">",
"      Evaluation and management of neonatal Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/49/11034?source=related_link\">",
"      Genetics and clinical presentation of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26280?source=related_link\">",
"      Hypospadias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=related_link\">",
"      Lipodystrophic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/14/34025?source=related_link\">",
"      Microdeletion syndromes (chromosomes 1 to 11)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21033?source=related_link\">",
"      Ovarian cysts and neoplasms in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/9/13464?source=related_link\">",
"      Pituitary gigantism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12408?source=related_link\">",
"      Unusual causes of adrenal insufficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10074="Osmotic demyelination syndrome and overly rapid correction of hyponatremia";
var content_f9_53_10074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10074/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10074/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10074/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10074/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/53/10074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/53/10074/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/53/10074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum sodium concentration is the primary determinant of the serum osmolality. The fall in serum osmolality in patients with true hyponatremia promotes water movement into the brain and, if the hyponatremia is acute and severe, can lead to cerebral edema and neurologic symptoms. In response to hyponatremia, the brain makes adaptations that lower the cerebral volume toward normal and reduces the likelihood of these complications. The mechanisms responsible for this cerebral adaptation are discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Brain adaptation to hyponatremia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H4#H4\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Osmolytes and cerebral adaptation to hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, brain adaptations that reduce the risk of cerebral edema make the brain vulnerable to injury if chronic hyponatremia is corrected too rapidly. The neurologic manifestations associated with overly rapid correction have been called the osmotic demyelination syndrome (ODS, formerly called central pontine myelinolysis). As will be described below, almost all patients who develop ODS present with a serum sodium concentration of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less.",
"   </p>",
"   <p>",
"    Issues related to ODS and the approach to the patient with unintentional overly rapid correction of hyponatremia will be reviewed here. A general overview of the treatment of hyponatremia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H138043002\">",
"    <span class=\"h2\">",
"     Hyponatremia with normal or elevated serum osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyponatremia do not always have a low serum osmolality. Depending upon the mechanism, such patients may or may not be at risk for either symptomatic hyponatremia or overly rapid correction and ODS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      True hyponatremia in patients with renal failure is usually associated with a normal or even elevated serum osmolality due to the increased blood urea nitrogen concentration. However, urea is an ineffective osmole, since it can equilibrate across the cell membrane. As a result, the effective serum osmolality is reduced in proportion to the degree of hyponatremia, and these patients can develop symptomatic hyponatremia and are at risk for ODS, although this a rare event in hemodialysis patients. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rapid rate of correction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hyponatremia can be associated with an elevated serum osmolality in patients with hyperglycemia, which pulls water out of the cells, thereby lowering the serum sodium by dilution. These patients are not at risk for symptomatic hyponatremia, since the high plasma osmolality results in water movement out of rather than into the brain.",
"     </li>",
"     <li>",
"      Hyponatremia with a normal serum osmolality can be an artifact of laboratory testing in patients with marked hyperlipidemia or hyperproteinemia, a phenomenon called pseudohyponatremia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H16#H16\">",
"     \"Causes of hyponatremia\", section on 'Hyponatremia with a high or normal serum osmolality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BRAIN ADAPTATION TO HYPONATREMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hyponatremia, defined as hyponatremia that is present for less than 48 hours, can lead to cerebral edema (due to osmotic water movement into the brain), which may be associated with seizures, coma, and death due to brain herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. This scenario can occur when large volumes of hypotonic or even isotonic fluids are given to postoperative patients, in whom pain, hypotension, nausea, and drugs can increase the secretion of antidiuretic hormone, thereby impairing the ability of the kidney to excrete water. Other causes of acute hyponatremia include water intoxication in marathon runners, psychotic patients, and users of the recreational drug ecstasy (methylenedioxymethamphetamine or MDMA) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H2#H2\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The brain adaptation begins shortly after an acute fall in serum sodium and is complete within two days. It is characterized initially by the loss of interstitial sodium and water into the cerebrospinal fluid due to increased hydraulic pressure and, within hours, by the loss of intracellular potassium, sodium, and organic solutes (called osmolytes) (",
"    <a class=\"graphic graphic_figure graphicRef71152 \" href=\"UTD.htm?26/22/26989\">",
"     figure 1",
"    </a>",
"    ). These processes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H4#H4\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Osmolytes and cerebral adaptation to hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The net effect of the cerebral adaptations is that hyponatremia which develops over more than two to three days is much less likely to be complicated by seizures and coma and is extremely unlikely to produce brain herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the rate of correction is important in this setting, since overly rapid correction of severe hyponatremia can lead to the osmotic demyelination syndrome (ODS, formerly called central pontine myelinolysis, but demyelination may be more diffuse and does not necessarily involve the pons) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7,8,11-13\">",
"     7,8,11-13",
"    </a>",
"    ]. In contrast, overly rapid correction is",
"    <strong>",
"     not",
"    </strong>",
"    likely to induce ODS in patients with severe hyponatremia that has only been present for several hours, since the cerebral adaptation is at an early stage. Examples include water intoxication in marathon runners, psychotic patients, and users of ecstasy; rapid correction does not usually lead to ODS in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OSMOTIC DEMYELINATION SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described in the preceding section, the osmotic demyelination syndrome (ODS) primarily occurs with overly rapid correction of severe hyponatremia (serum sodium concentration almost always 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less) that has been present for more than two to three days, which is the time required for the cerebral adaptation to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7-9,13\">",
"     7-9,13",
"    </a>",
"    ]. However, some patients are at high risk and can develop ODS at higher baseline serum sodium concentrations and lower rates of correction. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of ODS are typically",
"    <strong>",
"     delayed",
"    </strong>",
"    for two to six days after overly rapid elevation of the serum sodium concentration (",
"    <a class=\"graphic graphic_figure graphicRef76131 \" href=\"UTD.htm?19/46/20206\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/8,13-17\">",
"     8,13-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms, which are often irreversible or only partially reversible, include dysarthria, dysphagia, paraparesis or quadriparesis, behavioral disturbances, lethargy, confusion, disorientation, obtundation, and coma; seizures may also be seen but are less common [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/5,8,11-13\">",
"     5,8,11-13",
"    </a>",
"    ]. Severely affected patients may become \"locked in\"; they are awake, but are unable to move or communicate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;How the ODS occurs is not completely understood. Chronic hyponatremia is associated with the loss of osmotically active substances (sodium, potassium, chloride, and organic osmolytes such as myoinositol, glutamate, and glutamine) and water from brain cells, which provides protection against cerebral edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H4#H4\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Osmolytes and cerebral adaptation to hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these solutes cannot be as quickly replaced when the brain volume begins to shrink in response to correction of the hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. As a result, brain volume falls from a value that is initially somewhat above normal to one below normal with rapid correction of hyponatremia. Studies in rats have shown that demyelination primarily occurs in areas of the brain that are slowest in reaccumulating osmolytes after rapid correction of hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which a rapid fall in brain volume results in demyelination is not completely understood. One possible mechanism is that osmotic shrinkage of endothelial cells opens the blood-brain barrier, allowing the entry of complement and other cytotoxic plasma components. Another proposed mechanism is that, during recovery from hyponatremia, the loss of cell water coupled with the movement of potassium and sodium back into the cells leads to an initial increase in cell cation concentration that occurs before the repletion of organic osmolytes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/18,19,22\">",
"     18,19,22",
"    </a>",
"    ]. These combined changes may directly injure and induce apoptosis of astrocytes, leading to a disruption in the function of myelin producing oligodendrocytes, release of inflammatory cytokines, and activation of microglia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of risk factors have been identified for the development of ODS, with the most important being the serum sodium concentration at presentation, the duration of the hyponatremia, and the rate of correction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1957198\">",
"    <span class=\"h3\">",
"     Serum sodium at presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of ODS cases occur in patients whose sodium concentrations at presentation are less than or equal to 105",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and the vast majority of reported cases arise in patients who present with a serum sodium of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7-9,13\">",
"     7-9,13",
"    </a>",
"    ]. When the initial serum sodium is greater than 120",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    ODS is rare and typically limited to patients with severe liver disease who undergo liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/24\">",
"     24",
"    </a>",
"    ] or to patients with diabetes insipidus who become hyponatremic due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    therapy and who may rapidly correct and become hypernatremic after discontinuation of desmopressin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9515951\">",
"    <span class=\"h3\">",
"     Duration of hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in experimental animals showed that brain damage does not occur when hyponatremia of less than one day's duration is rapidly corrected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, if hyponatremia persists for two to three days or more, the same treatment results in usually fatal demyelinating brain lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/26-36\">",
"     26-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings have been noted in humans. Neurologic deterioration following rapid correction of hyponatremia is unlikely in patients with severe hyponatremia that develops over a few hours, particularly those whose normal water excretory capacity rapidly and spontaneously returns the serum sodium to normal. Examples include the ingestion of large amounts of water over several hours by marathon runners, psychotic patients, and users of ecstasy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In these patients, hyponatremia is short-lived and the brain does not have time to fully adapt. In contrast, patients who develop hyponatremia more gradually have time for the brain adaptation and may develop the ODS after rates of correction that are well tolerated in patients with self-induced acute water intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7-9,11-13\">",
"     7-9,11-13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Brain adaptation to hyponatremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the duration of hyponatremia is a major determinant of susceptibility to ODS, it is often not known. In this setting, it is safest to assume that the patient has chronic hyponatremia unless the history suggests acute water intoxication.",
"   </p>",
"   <p>",
"    Polydipsia does not always convey resistance to osmotic demyelination, since some polydipsic patients have hyponatremia of sufficient duration to permit cerebral adaptation. As an example, ODS has been reported in malnourished alcoholic patients with polydipsia and chronic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, alcoholism and malnutrition are risk factors for osmotic demyelination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H14#H14\">",
"     \"Causes of hyponatremia\", section on 'Primary polydipsia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H8\">",
"     'Other'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Rapid rate of correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in experimental animals suggest that the rate of correction of hyponatremia over a period of 24 hours is a more important determinant of the risk for osmotic demyelination than the maximum rate in any given hour [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. As in animals, the daily, rather than hourly rate of correction appears to be the primary determinant of risk in humans. Thus, our recommendations on the rate of correction of hyponatremia are based upon the daily, rather than hourly, rate of correction.",
"   </p>",
"   <p>",
"    Demyelinating lesions in experimental animals are most common and most severe when the serum sodium concentration in severe hyponatremia is raised more than 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 24 hours and are rare at a rate below 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/29\">",
"     29",
"    </a>",
"    ]. Similar findings have been noted in humans. Patients at greatest risk for irreversible and disabling brain injury are those who have severe hyponatremia for at least two to three days and in whom the serum sodium concentration is raised by more than 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 24 hours or is overcorrected to above 140",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7,11,12\">",
"     7,11,12",
"    </a>",
"    ]. In contrast, ODS is rare in chronically hyponatremic patients if the serum sodium concentration increases by less than 10 to 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 24-hour period",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    less than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 48-hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7-9,12,13,38\">",
"     7-9,12,13,38",
"    </a>",
"    ]. However, because occasional patients develop neurologic symptoms from osmotic demyelination even when corrected at 10 to 12",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per day, we agree with the 2007 hyponatremia treatment guidelines and other sources that recommend targeting a rate of correction of less than 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 24-hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7,9,12\">",
"     7,9,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Avoid overly rapid correction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overly rapid correction of hyponatremia can result from two mechanisms: following therapy that is specifically directed at raising the sodium concentration (usually hypertonic saline); and following cessation of a reversible stimulus to antidiuretic hormone (ADH) release. If renal function is normal, removal of the stimulus to ADH release results in a urine osmolality that is usually below 100",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    leading to rapid excretion of the excess water (called auto-correction).",
"   </p>",
"   <p>",
"    Auto-correction of the serum sodium can occur in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The administration of saline to patients with true volume depletion. Restoration of euvolemia rapidly suppresses the release of ADH (which has a half-life of only 15 to 20 minutes), thereby allowing excretion of the excess water [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of glucocorticoids to patients with adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/41-43\">",
"       41-43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=see_link&amp;anchor=H3#H3\">",
"       \"Hyponatremia and hyperkalemia in adrenal insufficiency\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Discontinuation of drugs that cause the syndrome of inappropriate ADH secretion (SIADH) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/38,44,45\">",
"       38,44,45",
"      </a>",
"      ]. These include a selective serotonin reuptake inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      . Desmopressin is used for the treatment of central diabetes insipidus, nocturnal enuresis in children, nocturia in adults, hemophilia, and von Willebrand disease, and can lead to hyponatremia in patients who drink large amounts of water [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/46\">",
"       46",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Drugs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Discontinuation of thiazide diuretics, since they interfere with urinary dilution [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=see_link\">",
"       \"Diuretic-induced hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spontaneous resolution of a transient cause for SIADH (eg, surgical stress, nausea, pneumonia).",
"     </li>",
"     <li>",
"      Treatment with a vasopressin receptor antagonist. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Vasopressin receptor antagonists'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Auto-correction of a reversible impairment in water excretion is an important reason why equations that are used to calculate the serum sodium response to a given fluid regimen frequently fail to predict the actual response. In a study of hyponatremic patients who were treated with hypertonic saline, for example, the actual rate of correction of the serum sodium exceeded the predicted rate in 29 of 39 patients (74 percent) whose pretreatment sodium concentration was less than 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/44\">",
"     44",
"    </a>",
"    ]. Ten patients had overly rapid correction; in these patients, the rise in serum sodium was 2.4 times the predicted value and was due to a documented water diuresis (defined as a low urine osmolality) in four.",
"   </p>",
"   <p>",
"    Another setting in which overly rapid correction can occur is in patients with end-stage renal disease who are treated with hemodialysis. Although osmotic demyelination syndrome can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], it is thought to be a rare event [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/50\">",
"     50",
"    </a>",
"    ]. The reasons why ODS is uncommon in patients treated with hemodialysis are not completely understood; however, one mechanism may be that the rise in serum osmolality induced by the rise in serum sodium during dialysis may be counterbalanced by a fall in serum osmolality induced by the removal of urea [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/31,50\">",
"     31,50",
"    </a>",
"    ]. Urea crosses the blood-brain barrier relatively slowly compared to osmotic water movement and therefore acts as an effective osmole when serum levels are reduced rapidly. Another possible mechanism is that azotemia enhances brain reuptake of organic osmolytes during correction of hyponatremia, minimizing cellular shrinking [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other factors appear to increase the susceptibility to osmotic demyelination, which can develop at less severe degrees of hyponatremia and slower rates of correction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/7,8,26,37,38,51,52\">",
"     7,8,26,37,38,51,52",
"    </a>",
"    ]. These include alcoholism, malnutrition, liver disease, and hypokalemia. Women of child bearing age are thought to be more susceptible to fatal cerebral edema associated with acute hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/2\">",
"     2",
"    </a>",
"    ]. However, there is no evidence that gender increases the risk of ODS.",
"   </p>",
"   <p>",
"    Some authors have emphasized the role of hypoxia in the pathogenesis of brain damage associated with hyponatremia, including the demyelinating brain lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. The genesis of this theory can be traced to a case series that included seven women who exhibited a biphasic neurological course, typical of osmotic demyelination, following hyponatremic seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/55\">",
"     55",
"    </a>",
"    ]. The author attributed these findings to seizure-induced brain anoxia and a delayed post-anoxic encephalopathy, a demyelinating disorder usually associated with carbon monoxide poisoning. However, in addition to an anoxic insult caused by seizures, these patients had also been treated with hypertonic saline with hyponatremia correction rates exceeding 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in less than 48 hours. It is not clear whether the brain damage sustained in these women was due to hypoxia, which can exacerbate brain swelling in experimental models of hyponatremia and may contribute to a fatal outcome, or whether these women had ODS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/53,54,56\">",
"     53,54,56",
"    </a>",
"    ]. Magnetic resonance imaging (MRI), which was not available at the time, might have detected the characteristic brain lesions of osmotic demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/12,26,38\">",
"     12,26,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3295564\">",
"    <span class=\"h2\">",
"     Detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demyelinating brain lesions associated with ODS can be occasionally detected by computerized tomography (CT) scanning or, much more reliably, by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/12,57-59\">",
"     12,57-59",
"    </a>",
"    ]. However, even MRI may not become positive for as long as four weeks after disease onset [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/12,57\">",
"     12,57",
"    </a>",
"    ]. Thus, an initially negative radiologic study in a patient who develops neurologic symptoms after overly rapid correction of hyponatremia does",
"    <strong>",
"     not",
"    </strong>",
"    exclude ODS. Earlier detection may be possible with newer imaging techniques such as diffusion-weighted imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the typically severe and permanent adverse consequences of ODS, prevention is essential. Among patients with hyponatremia lasting more than two to three days, or with hyponatremia of unknown duration, we recommend that the serum sodium be raised by less than 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 24-hour period and less than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 48-hour period to prevent ODS. The risk of ODS is greatest in patients with a serum sodium of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the duration of hyponatremia is a major determinant of susceptibility to ODS, it is often not known. In this setting, it is safest to assume that the patient has chronic hyponatremia unless the history suggests acute water intoxication.",
"   </p>",
"   <p>",
"    Formulas that estimate the effect of hypertonic saline therapy on the serum sodium concentration in hyponatremic patients often underestimate the rate of correction due, in some patients, to the emergence of a water diuresis (defined as a low urine osmolality) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the treatment of hyponatremia\", section on 'Estimation of the sodium deficit'",
"    </a>",
"    .) Thus, when correcting the serum sodium in patients with hyponatremia, fluid regimens based upon estimating equations should be considered as approximate calculations. Careful monitoring of the serum sodium concentration (initially every two to three hours) is",
"    <strong>",
"     essential",
"    </strong>",
"    to avoid overly rapid correction in patients at increased risk for ODS. In the absence of a persistent cause of impaired water excretion (eg, syndrome of inappropriate ADH secretion due to lung cancer or a brain tumor), the urine volume should also be monitored for the emergence of a water diuresis.",
"   </p>",
"   <p>",
"    Once therapy has been initiated to correct chronic hyponatremia (two to three days or more) in patients with a serum sodium of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less, some require further therapy because of an overly rapid rate of correction or because the initial trajectory of correction appears likely to exceed the maximum recommended goals. The choice of therapy varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relowering of the serum sodium may be beneficial in patients with a rate of correction that has exceeded the maximum recommended rate at 24 or 48 hours. This represents treatment of overly rapid correction.",
"     </li>",
"     <li>",
"      Slowing the rate of correction may be beneficial in patients whose trajectory of sodium correction is too rapid but has not yet exceeded the maximum rate of correction. This represents prevention of overly rapid correction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned above, these problems are most likely to result from an excessive rate of administration of hypertonic saline or from correction of the underlying cause of the hyponatremia as with volume repletion in hypovolemia and the administration of glucocorticoids in patients with adrenal insufficiency. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Rapid rate of correction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest the following approach to both treat and prevent overly rapid correction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/61\">",
"     61",
"    </a>",
"    ]. This approach involves the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP) to selected patients with or without 5 percent dextrose in water. The efficacy of desmopressin is presumably lessened in patients treated with vasopressin receptor antagonists but no data are available. The treatment of patients who have already developed ODS is described below but the regimen used is the same as that used to treat overly rapid correction. (See",
"    <a class=\"local\" href=\"#H44162660\">",
"     'Relowering the serum sodium to treat ODS'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Relowering the serum sodium to treat overly rapid correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest relowering in patients with an initial serum sodium concentration of 120",
"    <span class=\"nowrap\">",
"     meq/or",
"    </span>",
"    less that has been present for more than two to three days (or with an unknown duration of hyponatremia) in whom the rate of correction has exceeded maximum recommended goals (less than 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 24-hour period and less than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 48-hour period). The regimen is discussed below. (See",
"    <a class=\"local\" href=\"#H10601964\">",
"     'Regimen to relower the serum sodium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Animal models provide support for relowering the serum sodium in patients with hyponatremia that has been corrected too rapidly but do not have signs of ODS. Studies in rats have shown a marked reduction in the incidence and severity of brain lesions and in mortality when overly rapid correction of severe hyponatremia (by 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or more over several hours) is partially reversed within 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/30,35,36\">",
"     30,35,36",
"    </a>",
"    ]. In one study, for example, rats with a serum sodium less than 115",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for three days were rapidly corrected by more than 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    with a single intraperitoneal infusion of hypertonic saline [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/30\">",
"     30",
"    </a>",
"    ]. The rats treated with therapeutic relowering of the serum sodium survived free of neurologic signs. In contrast, all of the control rats died or developed neurologic signs such as hyperirritability and seizures. Significant benefit from relowering the serum sodium has also been described in rats that already had neurologic symptoms of overly rapid correction [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relowering of the serum sodium can reverse the breakdown of the blood-brain barrier that occurs with overly rapid correction and can prevent the infiltration of microglia that is a feature of osmotic demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/35\">",
"     35",
"    </a>",
"    ]. Relowering after overly rapid correction in rats is much more effective in preventing brain damage than the administration of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although human data are limited, relowering the serum sodium concentration with the administration of both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    and 5 percent dextrose in water (D5W) may abort osmotic demyelination following overly rapid correction of hyponatremia. The feasibility and apparent safety of relowering the serum sodium using desmopressin with or without D5W was described in a retrospective chart review of 20 hyponatremic patients who had either already exceeded the 24 hour correction goal (six patients) or whose trajectory was anticipated to result in overly rapid correction (14 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the six patients who had already exceeded the 24 hour correction goal (mean increase in serum sodium 15",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      range 12 to 20",
"      <span class=\"nowrap\">",
"       meq/L),",
"      </span>",
"      administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      and D5W prevented the 48-hour goal from being exceeded in five patients (mean 15",
"      <span class=\"nowrap\">",
"       meq/L).",
"      </span>",
"      The results in the 14 patients in whom overcorrection was anticipated are presented in the next section.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      lowered the serum sodium concentration by 4 to 9",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      below the peak level; the rate of relowering ranged from 0.3 to 0.9",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per hour.",
"     </li>",
"     <li>",
"      There were no adverse effects and all patients were discharged at their baseline level of health.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these observations demonstrate the feasibility of relowering of the serum sodium in patients with marked hyponatremia who have corrected too rapidly, they do not prove better outcomes than watchful waiting. Evidence for improved outcomes after relowering of the serum sodium is provided only by the rat models described above and by case reports of patients with overly rapid correction of severe hyponatremia (less than 110",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    who were treated with relowering because of neurologic symptoms compatible with ODS that resolved after relowering of the serum sodium by 12 to 16",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    over 12 to 14 hours with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    and oral or intravenous administration of dilute fluids (",
"    <a class=\"graphic graphic_figure graphicRef76131 \" href=\"UTD.htm?19/46/20206\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H44162660\">",
"     'Relowering the serum sodium to treat ODS'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Based upon these observations and the potentially devastating consequences of inaction, we suggest relowering in patients with an initial serum sodium concentration of 120",
"    <span class=\"nowrap\">",
"     meq/or",
"    </span>",
"    less that has been present for more than two to three days in whom the rate of correction has exceeded maximum recommended goals (less than 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 24-hour period and less than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 48-hour period).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10601964\">",
"    <span class=\"h4\">",
"     Regimen to relower the serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relowering regimen consists of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five percent dextrose in water (D5W), 6",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      lean body weight, infused over two hours. This quantity of D5W should lower the serum sodium by approximately 2",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      and the infusion should be repeated until the therapeutic goal, which is discussed below, is achieved.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      , 2 micrograms intravenously or subcutaneously every six hours; the dose can be increased to 4 micrograms in rare patients who do not respond to lower doses. The desmopressin is continued, even after D5W infusions have ceased, to prevent the serum sodium from rising again due to the excretion of dilute urine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The serum sodium should be measured after each infusion of D5W to determine the rate of relowering and whether or not the goal serum sodium has been achieved. The goals of therapy are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum should be lowered at an average rate of approximately 1",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      per hour.",
"     </li>",
"     <li>",
"      The goal serum sodium is one that represents a rate of correction of less than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in any 24-hour period and less than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in any 48-hour period. Assume, for example, a patient with an initial serum sodium of 115",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      is corrected to a serum sodium of 127",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in a period of 16 hours (overly rapid correction).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      and D5W should be given to lower the sodium to less than 125",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      within the next 8 hours, so that the net rate of correction over the 24-hour period is less than 10",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the goal serum sodium is achieved, the D5W is stopped, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is continued to prevent overly rapid correction, as described in the next section. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Desmopressin to prevent overly rapid correction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Desmopressin to prevent overly rapid correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with an initial serum sodium concentration of 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less have an initial trajectory of hyponatremia correction that appears likely to exceed the maximum recommended goals less than 10",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 24-hour period or less than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in any 48-hour period. This often occurs in association with the development of a water diuresis (ie, urine osmolality less than 200",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    when a reversible stimulus to increased ADH release has worn off [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Rapid rate of correction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In this setting, the best way to prevent overly rapid correction is the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    to concentrate the urine. Two exceptions are patients who cannot be relied upon to curtail water intake, and, because they are at low risk of osmotic demyelination, patients with hyperacute hyponatremia developing over a few hours due to a marked increase in water intake as can occur in marathon runners, psychotic patients, and users of ecstasy.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    with or without 5 percent dextrose in water (D5W) was evaluated in the retrospective chart review of 20 hyponatremic patients described in the preceding section [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/62\">",
"     62",
"    </a>",
"    ]. In the 14 patients in whom overcorrection was anticipated, administration of desmopressin uniformly maintained the correction rate below the 24-hour limit in 13 and below the 48-hour limit in all. In the five patients who also received D5W, the serum sodium fell 2 to 7",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    below the peak value. There were no adverse effects and, other than one elderly patient who died from shock, all patients were discharged at their baseline level of health.",
"   </p>",
"   <p>",
"    The usual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    regimen begins with 2 micrograms intravenously or subcutaneously. The maximum desmopressin dose is 4 micrograms in patients who do not respond to lower doses.",
"   </p>",
"   <p>",
"    There are two",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    regimens; both require fluid restriction and careful monitoring of the urine output and serum sodium:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One regimen is to give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      every six to eight hours. Since desmopressin produces a concentrated urine, correction of the hyponatremia will slow down or cease. If necessary, a slow infusion of hypertonic saline can then be added (10 to 30 mL per hour) to produce a rise in serum sodium at the desired rate [",
"      <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. The serum sodium should be measured every four to six hours, and the rate of hypertonic saline infusion should be adjusted if necessary. Desmopressin and, if used, hypertonic saline are continued until the serum sodium reaches 125 to 130",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Choice of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A second regimen is to give one dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      . Subsequent doses may be given after six to eight hours (or more) if the serum sodium is again rising too quickly or the urine output has increased dramatically. The urine output should be monitored hourly, since escape from the antidiuretic effect of desmopressin may be sudden and unpredictable; the serum sodium should be measured every two to three hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3296261\">",
"    <span class=\"h3\">",
"     Minocycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies examined the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    (a semisynthetic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ) on the prevention of osmotic demyelination in rats that underwent rapid correction of chronic hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In both studies, minocycline, given concurrently with hypertonic saline",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    within 24 hours of the correction of the hyponatremia, reduced the severity of neurologic symptoms and histologic demyelination.",
"   </p>",
"   <p>",
"    The rationale for evaluating the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    was provided by the following observations: minocycline crosses the blood brain barrier and inhibits microglial activation, thereby reducing microglial production of inflammatory cytokines; and minocycline has neuroprotective effects in experimental models of other demyelinating disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. There are no available data on minocycline use in humans with overly rapid correction of hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44162653\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ODS is associated with a poor prognosis and prevention is of primary importance. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Prevention'",
"    </a>",
"    above.) Among patients who develop ODS, there is support in both animal models and case reports in humans that relowering the serum sodium may be beneficial if initiated soon after the onset of neurologic symptoms of ODS. Supportive therapy is also important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44162660\">",
"    <span class=\"h3\">",
"     Relowering the serum sodium to treat ODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of relowering the serum sodium after the onset of neurologic symptoms of ODS was demonstrated in a rat model in which severe hyponatremia of three days duration was rapidly corrected with hypertonic saline by 30",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    at 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/36\">",
"     36",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the control rats, only 1 of 13 was still alive at 10 days (mean survival time 3.3 days).",
"     </li>",
"     <li>",
"      The outcomes were much better among rats treated with relowering the serum sodium with distilled water to a total correction of less than 20",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at 24 hours; seven survived and the mean survival time was 7.5 days. The rats treated four hours after symptom onset had better outcomes than those treated 8 to 10 hours after symptom onset.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data in humans are limited to case reports that suggest benefit from early relowering the serum sodium in patients who have developed symptoms of ODS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. As an example, a 71 year-old woman developed symptomatic hyponatremia with a serum sodium of 106",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in association with thiazide diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/15\">",
"     15",
"    </a>",
"    ]. The administration of isotonic saline was associated with an elevation in serum sodium of 21",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first 24 hours. After initial neurologic improvement, the patient deteriorated after 72 hours. The administration of hypotonic fluid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    relowered the serum sodium so that the final elevation was only 9",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    The patient recovered without neurologic sequelae.",
"   </p>",
"   <p>",
"    A similar outcome was described in another case report in which the serum sodium was raised by 23",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first 48 hours (",
"    <a class=\"graphic graphic_figure graphicRef76131 \" href=\"UTD.htm?19/46/20206\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/16\">",
"     16",
"    </a>",
"    ]. Relowering the serum sodium from 132 to 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    within the first 12 hours after the onset of neurologic manifestations consistent with ODS was associated with full neurologic recovery over the ensuing 36 hours.",
"   </p>",
"   <p>",
"    The optimal approach to the treatment of patients with serum sodium values that have corrected too rapidly and have developed neurologic manifestations consistent with ODS is unclear. Based upon the preceding observations of benefit, the absence of other effective therapies, and the poor prognosis associated with ODS, we recommend relowering the serum sodium to a level that is",
"    <strong>",
"     just below",
"    </strong>",
"    the maximal target value at 48 hours of less than 18",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    above the initial serum sodium. The 48-hour goal was chosen because patients with ODS typically present two to six days after overly rapid correction. The efficacy and safety of this approach is unknown.",
"   </p>",
"   <p>",
"    In the few case reports previously described, relowering with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    and 5 percent dextrose in water was initiated within hours of the onset of neurologic symptoms and there were substantial reductions in serum sodium (up to 12",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    within the first 12 hours (",
"    <a class=\"graphic graphic_figure graphicRef76131 \" href=\"UTD.htm?19/46/20206\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The optimal target serum sodium and rate of relowering in patients with ODS have not been defined. A reasonable approach is to lower the serum sodium to a value that is approximately 15 to 17",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    above the lowest level when therapy was initiated. As an example, a patient who presented with a serum sodium of 100",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    and develops symptoms of ODS with a serum sodium of 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    should have their sodium level lowered to approximately 115 to 117",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (ie, an increase just below 18",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    which is the 48-hour goal). &nbsp;",
"   </p>",
"   <p>",
"    The rate of relowering should be approximately 1",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    per hour. The patient's neurologic status and serum sodium should be carefully monitored as relowering is performed.",
"   </p>",
"   <p>",
"    Relowering therapy should be initiated as quickly as possible after the onset of neurologic symptoms that are attributed to ODS. In the rat model described above, initiation of relowering within four hours of symptom onset was associated with better outcomes than initiation within eight to ten hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/36\">",
"     36",
"    </a>",
"    ]. In the case reports in humans, relowering was initiated within a few hours after the onset of neurologic symptoms (",
"    <a class=\"graphic graphic_figure graphicRef76131 \" href=\"UTD.htm?19/46/20206\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. There is no evidence of benefit in humans when relowering is begun more than 24 hours after the onset of ODS symptoms, but clinicians may choose a trial of relowering in this setting.",
"   </p>",
"   <p>",
"    The regimens used to relower the serum sodium in patients with ODS are the same as those described below to relower the serum sodium in patients with overly rapid correction who have not developed manifestations of ODS. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Relowering the serum sodium to treat overly rapid correction'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44162667\">",
"    <span class=\"h3\">",
"     Supportive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with ODS recover function after prolonged periods of severe neurologic impairment. Thus, aggressive supportive therapy should be provided to all patients who were functional prior to the onset of ODS. Since patients with severe ODS frequently develop aspiration pneumonia and respiratory failure, endotracheal intubation and ventilator support are often required. Recovery from seemingly hopeless neurologic deficits can occur and, therefore, supportive therapy should be continued for at least six to eight weeks before concluding that the deficits are irreversible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/13,65\">",
"     13,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44162674\">",
"    <span class=\"h3\">",
"     Plasmapheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis is an experimental therapy for ODS that may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. A case report of three hyponatremic patients described aggressive plasmapheresis started immediately after the diagnosis of ODS was confirmed by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/53/10074/abstract/66\">",
"     66",
"    </a>",
"    ]. Although the pontine lesions were unchanged on repeat MRI, two patients markedly improved, with either no or clinically silent residual neurologic deficits, while the third had impaired intermediate-term memory and could walk only with assistance.",
"   </p>",
"   <p>",
"    Although these results suggest a possible benefit to plasmapheresis, they are difficult to interpret since some patients who undergo rapid correction of hyponatremia experience short-lived, spontaneously reversible episodes of neurologic impairment. Additional studies with a larger number of patients are required to clarify the role of plasmapheresis in the treatment of ODS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain adaptations that reduce the cerebral edema associated with hyponatremia make the brain vulnerable to injury if there is overly rapid correction of severe chronic hyponatremia (serum sodium 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less). The neurological manifestations of this injury have been called the osmotic demyelination syndrome (ODS, formerly called central pontine myelinolysis). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In hyponatremic patients, adaptations to return brain volume toward normal begin within minutes after an acute fall in the serum sodium concentration, and continue for days after the onset of hyponatremia. The net effect of the cerebral adaptations is that hyponatremia which develops over more than two to three days is much less likely to be complicated by seizures and coma and is extremely unlikely to produce brain herniation. However, these adaptation put patients at risk for ODS induced by overly rapid correction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Brain adaptation to hyponatremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of ODS, which are often irreversible or only partially reversible, are typically delayed for two to six days after the correction of the serum sodium concentration, and include dysarthria, dysphagia, paraparesis or quadriparesis, behavioral disturbances, lethargy, confusion, disorientation, obtundation, and coma; seizures may also be seen. Severely affected patients may develop a \"locked in\" syndrome; they are awake, but unable to move or communicate. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of ODS is not completely understood. Brain volume falls from a value that is initially somewhat above normal to one below normal with rapid correction of hyponatremia. Osmotic shrinkage of endothelial cells may disrupt the blood-brain barrier, allowing the entry of complement and other cytotoxic plasma components. Alternatively, the loss of cell water coupled with the movement of potassium and sodium back into the cells leads to an initial increase in cell cation concentration that occurs before the repletion of organic osmolytes. These combined changes may directly injure the brain cells. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three major risk factors for ODS are the serum sodium concentration at presentation, the duration of the hyponatremia, and the rate of correction. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The vast majority of cases of ODS occur in patients with a serum sodium concentration of 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less.",
"     </li>",
"     <li>",
"      ODS occurs in patients who have had severe hyponatremia for more than two to three days; the risk appears to be minimal in patients with hyponatremia of less than one day's duration.",
"     </li>",
"     <li>",
"      Almost all reported cases have occurred with elevations of the serum sodium of 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or more in any 24-hour period",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or more in any 48-hour period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Goals for correction of severe hyponatremia are based upon the",
"      <strong>",
"       daily",
"      </strong>",
"      , rather than hourly, rates of correction. In patients with severe hyponatremia that has been present for two or more days, or with hyponatremia of unknown duration, we recommend a rate of correction that is less than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in any 24-hour period and less than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in any 48-hour period (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The indications for raising the serum sodium in hyponatremic patients are discussed separately. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rapid rate of correction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"       \"Overview of the treatment of hyponatremia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The demyelinating brain lesions associated with the ODS can be detected with magnetic resonance imaging (MRI), but the MRI may not become positive for as long as four weeks after disease onset. Thus, an initially negative radiologic study in a patient who develops neurologic symptoms after overly rapid correction of hyponatremia does",
"      <strong>",
"       not",
"      </strong>",
"      exclude ODS. (See",
"      <a class=\"local\" href=\"#H3295564\">",
"       'Detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the potentially severe and permanent adverse consequences of ODS, prevention is essential. Use of estimating equations to prescribe a fluid regimen is not sufficient, and careful monitoring of the serum sodium concentration (initially every two to three hours) is necessary to avoid overly rapid correction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      to avoid overly rapid correction of hyponatremia, the usual regimen is 2 micrograms intravenously or subcutaneously at six to eight hour intervals. The maximum desmopressin dose is 4 micrograms in patients who do not respond to lower doses.",
"     </li>",
"     <li>",
"      In patients with an initial serum sodium concentration of 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less for more than two or three days, we suggest therapeutic relowering of the serum sodium if the rate of correction is more than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in any 24-hour period or more than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      any first 48-hour period (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest the following regimen (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Relowering the serum sodium to treat overly rapid correction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10601964\">",
"       'Regimen to relower the serum sodium'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Five percent dextrose in water (D5W), 6",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      lean body weight, infused over two hours. This quantity of D5W should lower the serum sodium by approximately 2",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      and the infusion should be repeated until the serum sodium falls to a level that represents a correction of less than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less than 18",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      depending upon when the overcorrection occurred.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      , 2 micrograms intravenously or subcutaneously every six hours; the dose can be increased to 4 micrograms in rare patients who do not respond to lower doses. The desmopressin is continued, even after D5W infusions have ceased, to prevent the serum sodium from rising again due to the excretion of dilute urine, as described in the next bullet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with an initial serum sodium concentration of 120",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      or less for more than two or three days (or of unknown duration)",
"      <strong>",
"       and",
"      </strong>",
"      an initial trajectory of hyponatremia correction that appears likely to exceed the maximum recommended goals of less than 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      any 24-hour period or less than 18",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      in any 48-hour period, we suggest one of the following two regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Desmopressin to prevent overly rapid correction'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One regimen is to give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      intravenously or subcutaneously every six to eight hours. Since desmopressin produces a concentrated urine, correction of the hyponatremia will slow down or cease. If necessary, a slow infusion of hypertonic saline can then be added (10 to 30 mL per hour) to produce a rise in serum sodium at the desired rate. The serum sodium should be measured every four to six hours, and the rate of hypertonic saline adjusted as needed. Desmopressin and, if used, hypertonic saline are continued until the serum sodium reaches 125 to 130",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"     </li>",
"     <li>",
"      The second regimen begins with a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      , with subsequent doses every six to eight hours if the serum sodium is again rising too quickly or the urine output has increased dramatically (indicating a water diuresis). The urine output should be monitored hourly, since escape from the antidiuretic effect of desmopressin may be sudden and unpredictable; the serum sodium should be measured every two to three hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no proven effective therapy for ODS, but a study in rats and a few case reports in patients suggest that relowering of the serum sodium can result in resolution of the ODS. A possible approach is described above. (See",
"      <a class=\"local\" href=\"#H44162660\">",
"       'Relowering the serum sodium to treat ODS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with ODS recover function after prolonged periods of severe neurologic impairment. Thus, aggressive supportive therapy should be provided to all patients who were functional prior to the onset of ODS, and should be continued for at least six to eight weeks before concluding that the deficits are irreversible. (See",
"      <a class=\"local\" href=\"#H44162667\">",
"       'Supportive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York City 2001. p.716.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/2\">",
"      Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 1992; 117:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/3\">",
"      Oster JR, Singer I. Hyponatremia, hyposmolality, and hypotonicity: tables and fables. Arch Intern Med 1999; 159:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/4\">",
"      Gross P. Treatment of severe hyponatremia. Kidney Int 2001; 60:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/5\">",
"      Moritz ML, Ayus JC. The pathophysiology and treatment of hyponatraemic encephalopathy: an update. Nephrol Dial Transplant 2003; 18:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/6\">",
"      Nzerue CM, Baffoe-Bonnie H, You W, et al. Predictors of outcome in hospitalized patients with severe hyponatremia. J Natl Med Assoc 2003; 95:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/7\">",
"      Sterns RH. Severe symptomatic hyponatremia: treatment and outcome. A study of 64 cases. Ann Intern Med 1987; 107:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/8\">",
"      Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994; 4:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/9\">",
"      Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007; 120:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/10\">",
"      Cheng JC, Zikos D, Skopicki HA, et al. Long-term neurologic outcome in psychogenic water drinkers with severe symptomatic hyponatremia: the effect of rapid correction. Am J Med 1990; 88:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/11\">",
"      Berl T. Treating hyponatremia: damned if we do and damned if we don't. Kidney Int 1990; 37:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/12\">",
"      Karp BI, Laureno R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. Medicine (Baltimore) 1993; 72:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/13\">",
"      Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986; 314:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/14\">",
"      Sterns RH, Hix JK, Silver S. Treatment of hyponatremia. Curr Opin Nephrol Hypertens 2010; 19:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/15\">",
"      Soupart A, Ngassa M, Decaux G. Therapeutic relowering of the serum sodium in a patient after excessive correction of hyponatremia. Clin Nephrol 1999; 51:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/16\">",
"      Oya S, Tsutsumi K, Ueki K, Kirino T. Reinduction of hyponatremia to treat central pontine myelinolysis. Neurology 2001; 57:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/17\">",
"      Croxson M, Lucas J, Bagg W. Diluting delirium. N Z Med J 2005; 118:U1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/18\">",
"      Lien YH, Shapiro JI, Chan L. Study of brain electrolytes and organic osmolytes during correction of chronic hyponatremia. Implications for the pathogenesis of central pontine myelinolysis. J Clin Invest 1991; 88:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/19\">",
"      Strange K. Regulation of solute and water balance and cell volume in the central nervous system. J Am Soc Nephrol 1992; 3:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/20\">",
"      McManus ML, Churchwell KB, Strange K. Regulation of cell volume in health and disease. N Engl J Med 1995; 333:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/21\">",
"      Yeates KE, Singer M, Morton AR. Salt and water: a simple approach to hyponatremia. CMAJ 2004; 170:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/22\">",
"      Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med 2006; 119:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/23\">",
"      Gankam Kengne F, Nicaise C, Soupart A, et al. Astrocytes are an early target in osmotic demyelination syndrome. J Am Soc Nephrol 2011; 22:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/24\">",
"      Yun BC, Kim WR, Benson JT, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology 2009; 49:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/25\">",
"      Davenport C, Liew A, Vic Lau P, et al. Central pontine myelinolysis secondary to hypokalaemic nephrogenic diabetes insipidus. Ann Clin Biochem 2010; 47:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/26\">",
"      Kleinschmidt-Demasters BK, Rojiani AM, Filley CM. Central and extrapontine myelinolysis: then...and now. J Neuropathol Exp Neurol 2006; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/27\">",
"      Sterns RH, Thomas DJ, Herndon RM. Brain dehydration and neurologic deterioration after rapid correction of hyponatremia. Kidney Int 1989; 35:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/28\">",
"      Mount DB. The brain in hyponatremia: both culprit and victim. Semin Nephrol 2009; 29:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/29\">",
"      Soupart A, Penninckx R, Stenuit A, et al. Treatment of chronic hyponatremia in rats by intravenous saline: comparison of rate versus magnitude of correction. Kidney Int 1992; 41:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/30\">",
"      Soupart A, Penninckx R, Crenier L, et al. Prevention of brain demyelination in rats after excessive correction of chronic hyponatremia by serum sodium lowering. Kidney Int 1994; 45:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/31\">",
"      Soupart A, Penninckx R, Stenuit A, Decaux G. Azotemia (48 h) decreases the risk of brain damage in rats after correction of chronic hyponatremia. Brain Res 2000; 852:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/32\">",
"      Soupart A, Silver S, Schro&ouml;eder B, et al. Rapid (24-hour) reaccumulation of brain organic osmolytes (particularly myo-inositol) in azotemic rats after correction of chronic hyponatremia. J Am Soc Nephrol 2002; 13:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/33\">",
"      Suzuki H, Sugimura Y, Iwama S, et al. Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia. J Am Soc Nephrol 2010; 21:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/34\">",
"      Gankam-Kengne F, Soupart A, Pochet R, et al. Minocycline protects against neurologic complications of rapid correction of hyponatremia. J Am Soc Nephrol 2010; 21:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/35\">",
"      Gankam Kengne F, Soupart A, Pochet R, et al. Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int 2009; 76:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/36\">",
"      Soupart A, Penninckx R, Stenuit A, et al. Reinduction of hyponatremia improves survival in rats with myelinolysis-related neurologic symptoms. J Neuropathol Exp Neurol 1996; 55:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/37\">",
"      Tanneau RS, Henry A, Rouhart F, et al. High incidence of neurologic complications following rapid correction of severe hyponatremia in polydipsic patients. J Clin Psychiatry 1994; 55:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/38\">",
"      Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol 2009; 29:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/39\">",
"      Oh MS, Uribarri J, Barrido D, et al. Danger of central pontine myelinolysis in hypotonic dehydration and recommendation for treatment. Am J Med Sci 1989; 298:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/40\">",
"      Lin SH, Chau T, Wu CC, Yang SS. Osmotic demyelination syndrome after correction of chronic hyponatremia with normal saline. Am J Med Sci 2002; 323:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/41\">",
"      Ahmed AB, George BC, Gonzalez-Auvert C, Dingman JF. Increased plasma arginine vasopressin in clinical adrenocortical insufficeincy and its inhibition by glucosteroids. J Clin Invest 1967; 46:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/42\">",
"      Lin SH, Hsu YJ, Chiu JS, et al. Osmotic demyelination syndrome: a potentially avoidable disaster. QJM 2003; 96:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/43\">",
"      Lasheen I, Doi SA, Al-Shoumer KA. Glucocorticoid replacement in panhypopituitarism complicated by myelinolysis. Med Princ Pract 2005; 14:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/44\">",
"      Mohmand HK, Issa D, Ahmad Z, et al. Hypertonic saline for hyponatremia: risk of inadvertent overcorrection. Clin J Am Soc Nephrol 2007; 2:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/45\">",
"      Pham PC, Chen PV, Pham PT. Overcorrection of hyponatremia: where do we go wrong? Am J Kidney Dis 2000; 36:E12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/46\">",
"      Gutenstein M. Osmotic myelinolysis syndrome after treatment of severe deamino arginine vasopressin-associated hyponatraemia: pitfalls in emergency medicine. Emerg Med Australas 2007; 19:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/47\">",
"      Mozes B, Pines A, Werner D, et al. Thiazide-induced hyponatremia: an unusual neurologic course. South Med J 1986; 79:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/48\">",
"      Tarhan NC, Agildere AM, Benli US, et al. Osmotic demyelination syndrome in end-stage renal disease after recent hemodialysis: MRI of the brain. AJR Am J Roentgenol 2004; 182:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/49\">",
"      Huang WY, Weng WC, Peng TI, et al. Central pontine and extrapontine myelinolysis after rapid correction of hyponatremia by hemodialysis in a uremic patient. Ren Fail 2007; 29:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/50\">",
"      Oo TN, Smith CL, Swan SK. Does uremia protect against the demyelination associated with correction of hyponatremia during hemodialysis? A case report and literature review. Semin Dial 2003; 16:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/51\">",
"      Martin RJ. Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. J Neurol Neurosurg Psychiatry 2004; 75 Suppl 3:iii22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/52\">",
"      Lohr JW. Osmotic demyelination syndrome following correction of hyponatremia: association with hypokalemia. Am J Med 1994; 96:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/53\">",
"      Vexler ZS, Ayus JC, Roberts TP, et al. Hypoxic and ischemic hypoxia exacerbate brain injury associated with metabolic encephalopathy in laboratory animals. J Clin Invest 1994; 93:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/54\">",
"      Knochel JP. Hypoxia is the cause of brain damage in hyponatremia. JAMA 1999; 281:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/55\">",
"      Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986; 314:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/56\">",
"      Ayus JC, Armstrong D, Arieff AI. Hyponatremia with hypoxia: effects on brain adaptation, perfusion, and histology in rodents. Kidney Int 2006; 69:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/57\">",
"      Brunner JE, Redmond JM, Haggar AM, et al. Central pontine myelinolysis and pontine lesions after rapid correction of hyponatremia: a prospective magnetic resonance imaging study. Ann Neurol 1990; 27:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/58\">",
"      Miller GM, Baker HL Jr, Okazaki H, Whisnant JP. Central pontine myelinolysis and its imitators: MR findings. Radiology 1988; 168:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/59\">",
"      Ruzek KA, Campeau NG, Miller GM. Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. AJNR Am J Neuroradiol 2004; 25:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/60\">",
"      Chu K, Kang DW, Ko SB, Kim M. Diffusion-weighted MR findings of central pontine and extrapontine myelinolysis. Acta Neurol Scand 2001; 104:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/61\">",
"      Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int 2009; 76:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/62\">",
"      Perianayagam A, Sterns RH, Silver SM, et al. DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 2008; 3:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/63\">",
"      Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 2002; 417:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/64\">",
"      Brundula V, Rewcastle NB, Metz LM, et al. Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 2002; 125:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/65\">",
"      Menger H, J&ouml;rg J. Outcome of central pontine and extrapontine myelinolysis (n = 44). J Neurol 1999; 246:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/66\">",
"      Bibl D, Lampl C, Gabriel C, et al. Treatment of central pontine myelinolysis with therapeutic plasmapheresis. Lancet 1999; 353:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/67\">",
"      Grimaldi D, Cavalleri F, Vallone S, et al. Plasmapheresis improves the outcome of central pontine myelinolysis. J Neurol 2005; 252:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/53/10074/abstract/68\">",
"      Saner FH, Koeppen S, Meyer M, et al. Treatment of central pontine myelinolysis with plasmapheresis and immunoglobulins in liver transplant patient. Transpl Int 2008; 21:390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2317 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10074=[""].join("\n");
var outline_f9_53_10074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H138043002\">",
"      Hyponatremia with normal or elevated serum osmolality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BRAIN ADAPTATION TO HYPONATREMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OSMOTIC DEMYELINATION SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1957198\">",
"      - Serum sodium at presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9515951\">",
"      - Duration of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Rapid rate of correction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3295564\">",
"      Detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Relowering the serum sodium to treat overly rapid correction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10601964\">",
"      Regimen to relower the serum sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Desmopressin to prevent overly rapid correction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3296261\">",
"      - Minocycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44162653\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44162660\">",
"      - Relowering the serum sodium to treat ODS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44162667\">",
"      - Supportive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44162674\">",
"      - Plasmapheresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2317\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2317|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/22/26989\" title=\"figure 1\">",
"      Osmolytes and hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/46/20206\" title=\"figure 2\">",
"      Time course of ODS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=related_link\">",
"      Diuretic-induced hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_53_10075="Infant hypoallergenic formula";
var content_f9_53_10075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F79377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F79377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypoallergenic formula options for infants with dietary protein-induced conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Extensively hydrolyzed casein protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Similac Alimentum",
"       </td>",
"       <td>",
"        (Abbott)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutramigen",
"       </td>",
"       <td>",
"        (Mead Johnson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutramigen with Enflora LGG",
"       </td>",
"       <td>",
"        (Mead Johnson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregestimil",
"       </td>",
"       <td>",
"        (Mead Johnson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Amino acid-based",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elecare Infant",
"       </td>",
"       <td>",
"        (Abbot)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neocate Infant DHA and ARA",
"       </td>",
"       <td>",
"        (Nutricia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Puramino (previously known as Nutramigen AA)",
"       </td>",
"       <td>",
"        (Mead Johnson)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alan Lake, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10075=[""].join("\n");
var outline_f9_53_10075=null;
var title_f9_53_10076="Drugs for HTV emergencies B";
var content_f9_53_10076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Parenteral drugs for treatment of hypertensive emergencies, continued*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Special indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Andrenergic inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Labetalol hydrochloride",
"       </td>",
"       <td>",
"        20-80 mg IV bolus every 10 min",
"       </td>",
"       <td rowspan=\"2\">",
"        5-10 min",
"       </td>",
"       <td rowspan=\"2\">",
"        3-6 h",
"       </td>",
"       <td rowspan=\"2\">",
"        Vomiting, scalp tingling, bronchoconstriction, dizziness, nausea, heart block, orthostatic hypotension",
"       </td>",
"       <td rowspan=\"2\">",
"        Most hypertensive emergencies except acute heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5-2.0 mg/min IV infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Esmolol hydrochloride",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        250-500 &micro;g/kg/min by infusion; may repeat bolus after 5 min or increase infusion to 300 &micro;g/min",
"       </td>",
"       <td>",
"        1-2 min",
"       </td>",
"       <td>",
"        10-30 min",
"       </td>",
"       <td>",
"        Hypotension, nausea, asthma, first-degree heart block, HF",
"       </td>",
"       <td>",
"        Aortic dissection, perioperative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phentolamine",
"       </td>",
"       <td>",
"        5-15 mg IV bolus",
"       </td>",
"       <td>",
"        1-2 min",
"       </td>",
"       <td>",
"        10-30 min",
"       </td>",
"       <td>",
"        Tachycardia, flushing, headache",
"       </td>",
"       <td>",
"        Catecholamine excess",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These doses may vary from those in the Physicians' Desk Reference (64th edition).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Hypotension may occur with all agents.",
"      <br>",
"       &Delta; Requires special delivery system.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10076=[""].join("\n");
var outline_f9_53_10076=null;
var title_f9_53_10077="Serotonin syndrome - Rapid overview";
var content_f9_53_10077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Serotonin syndrome: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical and laboratory features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The Hunter Criteria for serotonin syndrome (SS) are fulfilled if the patient has taken a serotonergic agent and has one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Spontaneous clonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inducible clonus and agitation or diaphoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ocular clonus and agitation or diaphoresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tremor and hyperreflexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypertonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Temperature above 38&deg;C and ocular clonus or inducible clonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SS is a clinical diagnosis; no laboratory test can confirm the diagnosis. SS can manifest a wide range of clinical symptoms from mild tremor to life-threatening hyperthermia and shock.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examination findings can include: hyperthermia, agitation, ocular clonus, tremor, akathisia, deep tendon hyperreflexia, inducible or spontaneous clonus, muscle rigidity, dilated pupils, dry mucus membranes, increased bowel sounds, flushed skin, and diaphoresis. Neuromuscular findings are typically more pronounced in the lower extremities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The following tests may be helpful in severe cases of SS to narrow the differential and to monitor potential complications:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Complete blood count, basic electrolytes, creatinine and BUN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Creatine phosphokinase, hepatic transaminases, coagulation studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blood culture, urinalysis, urine culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chest radiograph",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Head computed tomography, lumbar puncture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Differential diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuroleptic malignant syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticholinergic toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant hyperthermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sympathomimetic toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningitis or encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discontinue serotonergic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sedate using benzodiazepines (eg, lorazepam 1 to 2 mg IV per dose; 0.02 to 0.04 mg/kg/dose in children): goal is to eliminate agitation, neuromuscular abnormalities (eg, tremor, clonus), and elevations in heart rate and blood pressure; titrate dose to effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide: oxygen (maintain SpO2 &ge;94); IV fluids; continuous cardiac monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticipate complications; in severe SS vital signs can fluctuate widely and rapidly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If benzodiazepines and supportive care fail to improve agitation and abnormal vital signs, give cyproheptadine (12 mg orally or by orogastric tube for initial adult dose; pediatric doses included in main text)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat patients with temperature &gt;41.1&deg;C with immediate sedation, paralysis, and endotracheal intubation; treat hyperthermia with standard measures; avoid antipyretics such as acetaminophen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10077=[""].join("\n");
var outline_f9_53_10077=null;
var title_f9_53_10078="Decreased SIMV support in ARDS";
var content_f9_53_10078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of decreased synchronized intermittent mandatory ventilation (SIMV) support in acute respiratory distress syndrome (ARDS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 271px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effects of decreasing synchronized intermittent mandatory ventilation (SIMV) support on the work of breathing per liter of ventilation in patients with acute respiratory distress syndrome. Inspiratory work per unit volume (work per liter Wp/L) done by the patient is shown during assisted cycles (blue bars) and spontaneous cycles (red bars). As machine support was withdrawn, the patients performed an increasing amount of inspiratory work per liter of ventilation. The increased work was significantly greater at all levels of machine support less than or equal to 60 percent (p&le;0.01). Spontaneous breaths required 25 percent more work per liter of ventilation than assisted breaths at these levels of machine support. The pressure-time index exceeded a fatiguing level of work at all levels of machine support less than 80 percent. It was suggested that, when using the SIMV mode, the back-up rate should result in at least 80 percent of the minute ventilation coming from the machine in order to prevent fatigue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Marini JJ, Smith TC, Lamb V, Am Rev Respir Dis 1988; 138:1169.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10078=[""].join("\n");
var outline_f9_53_10078=null;
var title_f9_53_10079="Melanoma specific structures diagnostic accuracy";
var content_f9_53_10079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic accuracy of melanoma specific structures",
"    <sup>",
"     [1-4]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Melanoma specific structure",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Sensitivity (percent)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Specificity (percent)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Positive predictive value (percent)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Negative predictive value (percent)",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Odds ratio*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Amelanotic melanoma",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pigmented melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         1. Atypical network",
"        </strong>",
"        <sup>",
"         [1,3,5-14]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        21",
"       </td>",
"       <td class=\"centered\">",
"        35-82",
"       </td>",
"       <td class=\"centered\">",
"        62-89",
"       </td>",
"       <td class=\"centered\">",
"        18-67",
"       </td>",
"       <td class=\"centered\">",
"        71-88",
"       </td>",
"       <td class=\"centered\">",
"        1.1-9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2. Peripheral streaks",
"        </strong>",
"        (pseudopods and radial streaming)",
"        <sup>",
"         [1,3,5-10,13-15]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        9-32",
"       </td>",
"       <td class=\"centered\">",
"        77-99",
"       </td>",
"       <td class=\"centered\">",
"        22-77",
"       </td>",
"       <td class=\"centered\">",
"        54-86",
"       </td>",
"       <td class=\"centered\">",
"        1.6-5.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         3. Negative pigment network",
"        </strong>",
"        (asymmetrically located and disordered)",
"        <sup>",
"         [5,16]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        22",
"       </td>",
"       <td class=\"centered\">",
"        95",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         4. Blotch (off-centered)",
"        </strong>",
"        <sup>",
"         [13,14]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        4.1-4.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         5. Atypical dots and/or globules",
"        </strong>",
"        <sup>",
"         [3,6,7,13,14]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"       <td class=\"centered\">",
"        25-40",
"       </td>",
"       <td class=\"centered\">",
"        74-92",
"       </td>",
"       <td class=\"centered\">",
"        13-79",
"       </td>",
"       <td class=\"centered\">",
"        61-86",
"       </td>",
"       <td class=\"centered\">",
"        2.9-4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        <strong>",
"         6. Regression structures",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scar-like areas",
"        <sup>",
"         [1,3,5,8]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        23",
"       </td>",
"       <td class=\"centered\">",
"        17-36",
"       </td>",
"       <td class=\"centered\">",
"        93-99",
"       </td>",
"       <td class=\"centered\">",
"        89",
"       </td>",
"       <td class=\"centered\">",
"        70",
"       </td>",
"       <td class=\"centered\">",
"        4.4-18.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peppering",
"        <sup>",
"         [3,17]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        22",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        93-99",
"       </td>",
"       <td class=\"centered\">",
"        27",
"       </td>",
"       <td class=\"centered\">",
"        99",
"       </td>",
"       <td class=\"centered\">",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scar-like areas and peppering",
"        <sup>",
"         [3,5,6,13,14]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        22-42",
"       </td>",
"       <td class=\"centered\">",
"        93-99",
"       </td>",
"       <td class=\"centered\">",
"        78",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        3.9-7.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blue-white veil overlying macular areas and scar-like areas and peppering",
"        <sup>",
"         [11,12,18]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        44",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        91",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        3.1-8.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         7. Blue-white veil overlying raised areas",
"        </strong>",
"        <sup>",
"         [1,3,5,6,8,9,13,14]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"       <td class=\"centered\">",
"        17-75",
"       </td>",
"       <td class=\"centered\">",
"        86-99",
"       </td>",
"       <td class=\"centered\">",
"        52-73",
"       </td>",
"       <td class=\"centered\">",
"        55-70",
"       </td>",
"       <td class=\"centered\">",
"        2.5-13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         8. Atypical vascular structures",
"        </strong>",
"        <sup>",
"         [3,6,10,13,14,19-21]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        63",
"       </td>",
"       <td class=\"centered\">",
"        9.4",
"       </td>",
"       <td class=\"centered\">",
"        54-96",
"       </td>",
"       <td class=\"centered\">",
"        69",
"       </td>",
"       <td class=\"centered\">",
"        53",
"       </td>",
"       <td class=\"centered\">",
"        1.5-7.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dotted + serpentine",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        85",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serpentine vessels",
"        <sup>",
"         [3,22]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        34",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        80",
"       </td>",
"       <td class=\"centered\">",
"        68",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polymorphous vessels",
"        <sup>",
"         [3,22]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        68",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        2.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Milky-red areas",
"        <sup>",
"         [3,22]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        51",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        71",
"       </td>",
"       <td class=\"centered\" rowspan=\"2\">",
"        <br/>",
"        <p>",
"         77.8",
"        </p>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Red globules",
"        <sup>",
"         [3,22]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        21",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        88",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         9. Crystalline structures",
"        </strong>",
"        (also known as Chrysalis and shiny white streaks)",
"        <sup>",
"         [23]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        9.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         10. Brown peripheral structureless areas",
"        </strong>",
"        <sup>",
"         [3,6]",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        19",
"       </td>",
"       <td class=\"centered\">",
"        63",
"       </td>",
"       <td class=\"centered\">",
"        93-96",
"       </td>",
"       <td class=\"centered\">",
"        94",
"       </td>",
"       <td class=\"centered\">",
"        73",
"       </td>",
"       <td class=\"centered\">",
"        2.9-28",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The odds ratios for the diagnosis of melanoma shown in the table are statistically significant since the 95% confidence intervals do not include the unit.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      When involving &gt;50 percent of the lesion.",
"      <br>",
"       &Delta; When involving &lt;50 percent of the lesion.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Soyer HP, Smolle J, Leitinger G, et al. Diagnostic reliability of dermoscopic criteria for detecting malignant melanoma. Dermatol 1995; 190:25.",
"       </li>",
"       <li>",
"        Marghoob AA, Korzenko AJ, Changchien L, et al. The beauty and the beast sign in dermoscopy. Dermatol Surg 2007; 33:1388.",
"       </li>",
"       <li>",
"        Menzies SW, Kreusch J, Byth K, et al. Dermoscopic evaluation of amelanotic and hypomelanotic melanoma . Arch Dermatol 2008; 144:1120.",
"       </li>",
"       <li>",
"        Stoecker WV, Stolz W. Dermoscopy and the diagnostic challenge of amelanotic and hypomelanotic melanoma. Arch Dermatol 2008; 144:1207.",
"       </li>",
"       <li>",
"        Menzies SW, Ingvar C, McCarthy WH. A sensitivity and specificity analysis of the surface microscopy features of invasive melanoma. Melanoma Res 1996; 6:55.",
"       </li>",
"       <li>",
"        Annessi G, Bono R, Sampogna F, et al. Sensitivity, specificity, and diagnostic accuracy of three dermoscopic algorithmic methods in the diagnosis of doubtful melanocytic lesions: the importance of light brown structureless areas in differentiating atypical melanocytic nevi from thin melanomas. J Am Acad Dermatol 2007; 56:759.",
"       </li>",
"       <li>",
"        Haenssle HA, Korpas B, Hansen-Hagge C, et al. Seven-point checklist for dermatoscopy: performance during 10 years of prospective surveillance of patients at increased melanoma risk. J Am Acad Dermatol 2010; 62:785.",
"       </li>",
"       <li>",
"        Salopek TG, Kopf AW, Stefanato CM, et al. Differentiation of atypical moles (dysplastic nevi) from early melanomas by dermoscopy. Dermatol Clin 2001; 19:337.",
"       </li>",
"       <li>",
"        Kenet RO, Kang S, Kenet BJ, et al. Clinical diagnosis of pigmented lesions using digital epiluminescence microscopy. Grading protocol and atlas. Arch Dermatol 1993; 129:157.",
"       </li>",
"       <li>",
"        Pizzichetta MA, Stanganelli I, Bono R, et al. Dermoscopic features of difficult melanoma. Dermatol Surg 2007; 33:91.",
"       </li>",
"       <li>",
"        Soyer HP, Argenziano G, Zalaudek I, et al. Three-point checklist of dermoscopy. A new screening method for early detection of melanoma. Dermatology 2004; 208:27.",
"       </li>",
"       <li>",
"        Zalaudek I, Argenziano G, Soyer HP, et al. Three-point checklist of dermoscopy: an open internet study. Br J Dermatol 2006; 154:431.",
"       </li>",
"       <li>",
"        Argenziano G, Fabbrocini G, Carli P, et al. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998; 134:1563.",
"       </li>",
"       <li>",
"        Argenziano G, Chimenti S, Talamini R, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.",
"       </li>",
"       <li>",
"        Dal Pozzo V, Benelli C, Roscetti E. The seven features for melanoma: a new dermoscopic algorithm for the diagnosis of malignant melanoma. Eur J Dermatol 1999; 9:303.",
"       </li>",
"       <li>",
"        Marghoob AA. Unpublished data.",
"       </li>",
"       <li>",
"        Braun RP, Gaide O, Oliviero M, et al. The significance of multiple blue-grey dots (granularity) for the dermoscopic diagnosis of melanoma. Br J Dermatol 2007; 157:907.",
"       </li>",
"       <li>",
"        Zalaudek I, Argenziano G, Ferrara G, et al. Clinically equivocal melanocytic skin lesions with features of regression: a dermoscopic-pathological study. Br J Dermatol 2004; 150:64.",
"       </li>",
"       <li>",
"        Bono A, Maurichi A, Moglia D, et al. Clinical and dermatoscopic diagnosis of early amelanotic melanoma. Melanoma Res 2011; 11:491.",
"       </li>",
"       <li>",
"        Pizzichetta MA, Talamini R, Stanganelli I, et al. Amelanotic/hypomelanotic melanoma: Clinical and dermoscopic features. Br J Dermatol 2004; 150:1117.",
"       </li>",
"       <li>",
"        Puig S, Argenziano G, Zalaudek I, et al. Melanomas that failed dermoscopic detection: A combined clinicodermoscopic approach for not missing melanoma. Dermatol Surg 2007; 33:1262.",
"       </li>",
"       <li>",
"        Argenziano G, Zalaudek I, Corona R, et al. Vascular structures in skin tumors: a dermoscopy study. Arch Dermatol 2004; 140:1485.",
"       </li>",
"       <li>",
"        Balagula Y, Braun RP, Rabinovitz HS, et al. The significance of crystalline/chrysalis structures in the diagnosis of melanocytic and nonmelanocytic lesions. J Am Acad Dermatol 2011. Epub ahead of print.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_53_10079=[""].join("\n");
var outline_f9_53_10079=null;
